



Final Screening Assessment for *Candida utilis* ATCC 9950

**Environment and Climate Change Canada
Health Canada**

May 2016

Cat. No.: En14-249/2016E-PDF
ISBN 978-0-660-05035-5

Information contained in this publication or product may be reproduced, in part or in whole, and by any means, for personal or public non-commercial purposes, without charge or further permission, unless otherwise specified.

You are asked to:

- Exercise due diligence in ensuring the accuracy of the materials reproduced;
- Indicate both the complete title of the materials reproduced, as well as the author organization; and
- Indicate that the reproduction is a copy of an official work that is published by the Government of Canada and that the reproduction has not been produced in affiliation with or with the endorsement of the Government of Canada.

Commercial reproduction and distribution is prohibited except with written permission from the author. For more information, please contact Environment and Climate Change Canada's Inquiry Centre at 1-800-668-6767 (in Canada only) or 819-997-2800 or email to ec.enviroinfo.ec@canada.ca.

© Her Majesty the Queen in Right of Canada, represented by the Minister of the Environment and Climate Change, 2016.

Aussi disponible en français

Synopsis

Pursuant to paragraph 74(b) of the *Canadian Environmental Protection Act*, 1999 (CEPA 1999), the Minister of Environment and Climate Change and the Minister of Health have conducted a screening assessment of *Candida utilis* ATCC 9950.

C. utilis ATCC 9950 is a yeast that has characteristics in common with other strains of the species *C. utilis*. *C. utilis* can adapt to varying conditions and thrives in soil and water. Multiple potential uses of *C. utilis* in consumer, industrial, commercial and agricultural sectors exist. These include production of food, natural health products, feeds, biochemicals used in cosmetics and therapeutic drugs, bioremediation and wastewater treatment.

C. utilis has an established history of use as a feed supplement in aquaculture, swine, poultry, and livestock diets, yet only two incidents of infection in vertebrates have been attributed to *C. utilis*. In both cases, the affected animals had pre-existing conditions and the infections were effectively treated with antifungals. No reports in the literature showed significant effects of *C. utilis* in terrestrial or aquatic plants or invertebrates. Certain strains of *C. utilis* have anti-algal, antibacterial and anti-fungal properties, which allow its use as a biocontrol agent against pest micro-organisms.

Although *C. utilis* has also been extensively used in the food industry, the incidence of human infection with *C. utilis* is exceedingly low. There have been no reported human infections attributed specifically to the *Domestic Substances List* (DSL) strain *C. utilis* ATCC 9950; however, some strains of *C. utilis* can act as opportunistic pathogens in susceptible individuals, particularly those who have a weakened immune system or underlying medical conditions.

This assessment considers the aforementioned characteristics of *C. utilis* ATCC 9950 with respect to environmental and human health effects associated with consumer and commercial product use and industrial processes subject to CEPA 1999, including releases to the environment through waste streams and incidental human exposure through environmental media. A conclusion under CEPA 1999 on this living organism has no bearing on and does not preclude assessments, authorized under *the Food and Drugs Act*, of products produced by or containing *C. utilis* ATCC 9950. *C. utilis* ATCC 9950 was nominated to the DSL for use in the food industry. To update information on current uses, the Government launched a mandatory information-gathering survey under section 71 of CEPA 1999 (section 71 notice) as published in the *Canada Gazette*, Part I, on October 3, 2009. Information submitted in response to the notice indicates that *C. utilis* ATCC 9950 was imported into Canada in 2008 for use in food production and processing. No uses related to consumer products were reported in Canada.

Considering all available lines of evidence presented in this screening assessment, there is low risk of harm to organisms and the broader integrity of the environment from *C. utilis* ATCC 9950. It is concluded that *C. utilis* ATCC 9950 does not meet the criteria under paragraph 64(a) or (b) of CEPA as it is not entering the environment in

a quantity or concentration or under conditions that have or may have an immediate or long-term harmful effect on the environment or its biological diversity or that constitute or may constitute a danger to the environment on which life depends.

Based on the information presented in this screening assessment, it is concluded that *C. utilis* ATCC 9950 does not meet the criteria under paragraph 64(c) of CEPA as it is not entering the environment in a quantity or concentration or under conditions that constitute or may constitute a danger in Canada to human life or health.

Table of Contents

Synopsis	ii
Introduction	vii
Decisions from Domestic and International Jurisdictions	viii
Domestic.....	viii
International	viii
Hazard Assessment.....	1
1.1 Characterization of <i>Candida utilis</i>	1
1.1.1 Taxonomic identification and strain history	1
1.2 Biological and ecological properties.....	7
1.2.1 Natural occurrence.....	7
1.2.2 Growth conditions	8
1.2.3 Nutrient cycling	9
1.2.4 Biocontrol	10
1.2.5 Biosorption of metals	10
1.2.6 Susceptibility to chemical agents and antifungals	11
1.2.7 Pathogenic and toxigenic properties.....	12
1.3 Effects.....	14
1.3.1 Environment.....	14
1.3.2 Humans.....	16
1.4 Hazard severity	17
Exposure Assessment	18
2.1 Sources of exposure	18
2.2 Exposure characterization.....	20
2.2.1 Environment.....	20
2.2.2 Human	21
Risk Characterization.....	21
Conclusion	23
References.....	24
Appendices	38
Appendix A: Characterization <i>C. utilis</i> ATCC 9950	38

List of Tables

Table 1-1: Morphological properties of <i>C. utilis</i> ATCC 9950	2
Table 1-2: Biochemical properties of <i>C. utilis</i> ATCC 9950	3
Table 1-3: Molecular properties of <i>C. utilis</i> ATCC 9950 predicted from shotgun sequences	6
Table 1-4: Minimal inhibitory concentrations of antifungal agents for <i>C. utilis</i> ATCC 9950.....	11
Table A-1: Growth of <i>C. utilis</i> ATCC 9950 on various media and temperatures	38

List of Figures

Figure 1-1: Fatty acid methyl ester (FAME) analysis of <i>C. utilis</i> ATCC 9950 using MIDI YST28 Yeast Database	4
Figure 1-2: Phylogenetic analysis of select <i>Candida</i> species based on the alignment of the ITS1 and ITS2 sequences of the 18S and 28S rRNA genes.....	6
Figure 1-3: Persistence of <i>C. utilis</i> ATCC 9950, based on qPCR analyses of extractable soil DNA	8
Figure A-1: Growth of a) <i>C. utilis</i> ATCC 9950 and b) <i>C. albicans</i> SC5314 on Corn Meal-Tween 80 Agar at 37°C for 72 h.....	38

Introduction

Pursuant to paragraph 74(b) of the *Canadian Environmental Protection Act, 1999* (CEPA 1999), the Minister of Environment and the Minister of Health are required to conduct screening assessments of those living organisms added to the Domestic Substances List (DSL) by virtue of section 105 of the Act, to determine whether they present or may present a risk to the environment or human health (according to criteria as set out in section 64 of CEPA 1999).¹ *Candida utilis* ATCC 9950 was added to the DSL under subsection 25(1) of CEPA 1988 and the DSL under subsection 105(1) of CEPA 1999 because it was manufactured in or imported into Canada between January 1, 1984 and December 31, 1986 and entered or was released into the environment without being subject to conditions under CEPA 1999 or any other Act of Parliament or of the legislature of a province.

This screening assessment considers hazard information obtained from the public domain and from unpublished research data, as well as comments from scientific peer reviewers. Exposure information was also obtained from the public domain and from a mandatory CEPA 1999 section 71 Notice published in the *Canada Gazette*, Part I, on October 3, 2009. Further details on the risk assessment methodology used are available in the Risk Assessment Framework document entitled “[Framework on the Science-Based Risk Assessment of Micro-organisms under the Canadian Environmental Protection Act, 1999](#)” (Environment Canada and Health Canada 2011).

In this report, data that are specific to the DSL-listed strain, *C. utilis* ATCC 9950, are identified as such. Strain-specific data include information from the Nominator, the American Type Culture Collection (ATCC) and unpublished data generated by Health Canada² and Environment Canada³ research scientists. Where strain-specific data were not available, surrogate information from literature searches was used. When applicable, literature searches conducted on the organism included its synonyms, and common and superseded names. Surrogate organisms are identified in each case to the taxonomic level provided by the source. Literature searches were conducted using scientific literature databases (SCOPUS, CAB Abstracts, and NCBI PubMed), web searches, and key search terms for the identification of human health and environmental hazards. Information identified up to June 2014 was considered for inclusion in this screening assessment report.

¹ A determination of whether one or more criteria of section 64 of CEPA 1999 are met is based on an assessment of potential risks to the environment and/or to human health associated with exposure in the general environment. For humans, this includes, but is not limited to, exposure from air, water and the use of products containing the substances. A conclusion under CEPA 1999 may not be relevant to, nor does it preclude, an assessment against the criteria specified in the *Controlled Products Regulations*, which is part of the regulatory framework for the Workplace Hazardous Materials Information System (WHMIS) for products intended for workplace use.

² Testing conducted by Health Canada's Environmental Health Science and Research Bureau

³ Testing conducted by Environment Canada's Biological Methods Division

Decisions from Domestic and International Jurisdictions

Domestic

The Public Health Agency of Canada (PHAC) assigned *C. utilis* (as a species) to Risk Group 1 (low individual and community risk) for both humans and terrestrial animals (personal communication, PHAC 2014).

The Canadian Food Inspection Agency (CFIA) does not consider *C. utilis* as a regulated plant pest in Canada (personal communication, CFIA 2014). In addition, single ingredient feeds containing dehydrated Yeast *Torula* (common name for *C. utilis*), are exempt from the registration requirement under Part I, Schedule IV of the *Feeds Regulations* (CFIA 2014).

C. utilis, listed as dried *Torula* yeast, is an approved non-medicinal ingredient in the Natural Health Products Ingredients Database (NHPID). It can be safely used provided the total folic acid content of the yeast does not exceed 0.04 milligram per gram of yeast as permitted by the U.S. FDA and it must also comply with the monograph for Yeast, dried in the Food Chemicals Codex (Health Canada 2015).

International

In 2013, the United States Food and Drug Administration (U.S. FDA) under Section 172.896 of the Code of Federal Regulations permitted the use of dried *C. utilis* (also referred as *Torula* yeast) as a food additive for human consumption provided that the total folic acid of the yeast does not exceed 0.04 mg/g of yeast (U.S. FDA 2013).

Hazard Assessment

1.1 Characterization of *Candida utilis*

1.1.1 Taxonomic identification and strain history

Binomial name *Candida utilis* (*C. utilis*)

Taxonomic designation

Kingdom	Fungi
Phylum	Ascomycota
Subphylum	Saccharomycotina
Class	Saccharomycetes
Order	Saccharomycetidae
Family	<i>Saccharomycetales</i>
Genus	<i>Candida</i>
Species	<i>utilis</i> (Henneberg) Lodder et Kreger-van Rij (1952)
Strain	ATCC 9950 (equivalent to NRRL Y-900, CBS 5609, DSM 2361, NBRC 0988)

Superseded names: *Torula utilis* Henneberg, *Saccharomyces jadinii* (Sartory, R. Sartory, Weill & J. Meyer), *Torulopsis utilis* (Henneberg) Lodder var. *utilis*

Anamorph of: *Hansenula jadinii* (Sartory, R. Sartory, Weill & J. Meyer), *Pichia jadinii* (Sartory et al.) Wickerham, *Lindnera jadinii* (A. & R. Sartory, Weill & J. Meyer), *Cyberlindnera jadinii* (R. Sartory, R. Sartory, Weill & J. Meyer).

C. utilis is an asexual non-filamentous ascomycete. It is the asexual (anamorph) state of *Pichia* (*Hansenula*, *Cyberlindnera*) *jadinii* (Kurtzman et al. 1979; Yamada et al. 1995). Regardless of the reproductive state, the names *P. jadinii* and *C. utilis* have been used synonymously in numerous publications (Kurtzman 1988, Barnett 2004).

Common names: Torula Yeast, Fodder Yeast

Strain history

According to the United States Department of Agriculture's ARS Culture Collection, the organism was originally isolated from animal fodder (USDA ARS 2014). It was deposited at the USDA ARS Culture Collection (NRRL) as NRRL Y-900 and to the American Type Culture Collection as ATCC accession number 9950. The strain was also deposited in various culture collections with the following designations: CCRC 20325, IFO 0988, NCYC 707, NRCC 2721, VTT C-78085.

1.1.1.2 Phenotypic and molecular characteristics

The genus *Candida* contains over 150 species (Barnett et al. 2000; Dorko et al. 2000). With the exceptions of *C. glabrata* and *C. krusei*, almost all of the pathogenic *Candida* species, including *C. albicans*, *C. tropicalis*, *C. dubliniensis*, and *C. parapsilosis*, belong in a single *Candida* clade characterized by the unique translation of CUG codons as serine rather than leucine (Butler et al. 2009). *C. utilis*, on the other hand, is a member of a distinct clade separate from other *Candida* yeasts including those commonly associated with human disease (Buerth et al. 2011; Tomita et al. 2012).

The purpose of this section is to describe methodologies that can be used to distinguish between *C. utilis* and other *Candida* species, particularly *C. albicans* which is a commensal gut yeast in humans but is also the most common cause of opportunistic fungal infection. A polyphasic approach is important in generating a robust taxonomic identification that allows for clear differentiation of *C. utilis* from closely-related pathogenic *Candida* species.

In clinical settings, culture-based rapid identification methods based on biochemical and metabolic endpoints, such as the *Candida* ID, API *Candida*, API 20C, API ID 32C, VITEK System, and RapID Yeast Plus (Barnett et al. 2000; Fricker-Hidalgo et al. 2001; Hata et al. 2007; Verweij et al. 1999) are often used for the diagnostic identification of *Candida* and other clinically relevant yeasts.

Phenotypic properties comparing *C. utilis* ATCC 9950 with *C. albicans* are summarized in Tables 1-1 and 1-2. Morphology of *C. utilis* on chromogenic agar, corn meal-Tween 80 agar and in a germ tube test is distinctly different (Table 1-1).

Table 0-1: Morphological properties of *C. utilis* ATCC 9950

Characteristic	<i>C. utilis</i> ATCC 9950 (DSL strain) ^a	<i>C. albicans</i> ATCC MYA-2786 (equivalent to SC5314) ^a
Chromogenic agar	Circular, pink, glossy	Circular, green smooth
Corn meal-Tween 80 agar	Pseudohyphae No chlamydospore	Hyphae Chlamydospores
Germ tube test	Negative	Positive
Czapek agar	3 mm diameter, circular, entire, flat-convex, white/off-white, moist, opaque	1 mm diameter, circular, entire, flat-convex, white/off-white, opaque

^a Unpublished data generated by Health Canada's Healthy Environments and Consumer Safety Branch. Refer to Appendix A Figure A-1 for growth on Corn Meal Tween agar and Table A-1 for growth on various media at temperatures

In contrast to *C. albicans*, *C. utilis* does not form chlamydospores (Kondo et al. 1995; NCYC 2014) (shown in Figure A-1), which when present in *C. albicans* are developed at true hyphal extremities. The presence of chlamydospores is the basis of a method for rapid presumptive identification of *Candida* species infection: the germ tube test (Sheppard et al. 2008).

In contrast to the true hyphae seen in *C. albicans*, *C. utilis* (including ATCC 9950) produces only simple pseudohyphae (Kurtzman et al. 1979) (Refer to Figure A-1). Structurally, hyphae are narrower and more uniform than pseudohyphal buds, which have a constriction between the mother and daughter cells (reviewed in Sudbery et al. 2004).

Table 0-2: Biochemical properties of *C. utilis* ATCC 9950

Characteristic	<i>C. utilis</i> ATCC 9950 (DSL strain)	<i>C. albicans</i> ATCC MYA-2786 (equivalent to SC5314)
Growth at 37°C on YPD	Yes (CBS-KNAW, 2014)	Yes (Thewes et al. 2008)
Growth at 42°C on YPD	No (CBS-KNAW, 2014)	Yes (Lorenz and Fink, 2001)
Crabtree effect (production of ethanol in aerobic condition)	Negative (Tomita et al. 2012)	Negative (Helmerhorst et al. 2006)
Trehalose assimilation	Negative ^a	Positive ^a
Maltose assimilation	Negative ^a	Positive ^a
Sucrose assimilation	Positive ^a	Positive ^a
L-rhamnose assimilation	Negative (Kurtzman et al. 1979)	Negative (CBS-KNAW, 2014)

^a Unpublished data generated by Health Canada's Healthy Environments and Consumer Safety Branch.

Fatty acid compositional analysis, shown in Figure1-1, was conducted by Health Canada scientists on *C. utilis* ATCC 9950 using GC-FAME and the Sherlock[®] MIDI Microbial Identification System.




Figure 0-1: Fatty acid methyl ester (FAME) analysis of *C. utilis* ATCC 9950 using MIDI YST28 Yeast Database

Based on cellular fatty acid composition, the DSL *C. utilis* strain, ATCC 9950, is not closely related to *C. albicans*. Similarly, Singh et al. (2010) demonstrated that *C. utilis* has a very distinctive phospholipid profile compared to *C. albicans* using electrospray ionization tandem mass spectrometry.

The secreted proteome of *C. utilis* ATCC 9950, grown on SD medium, was analyzed by Buerth et al. (2011) using mass spectroscopy. A total of 37 proteins were identified and compared with the secreted proteome of *Saccharomyces cerevisiae*, *C. albicans* and *C. glabrata*. Most of the *C. utilis* ATCC 9950 secreted proteins, such as glucanases, glucanosyltransferase, chitin transglycosylase, and thioredoxin, are homologous and function similarly to those secreted by *C. albicans* and *C. glabrata*. These proteins are used for cell wall assembly and maintenance, and stress response. Others are unique to *C. utilis* ATCC 9950, and their presence could be helpful in its identification. They include proteins associated with carbon metabolism and nitrate assimilation, such as invertase and asparaginase, respectively (Buerth et al. 2011). Proteins related to pathogenicity in *C. albicans*, such as aspartyl proteases and the Op4 protein, were not detected in *C. utilis* ATCC 9950 (Buerth et al. 2011). For more details about the role of these proteins in pathogenicity, refer to section 1.2.9.

Phylogenetic analysis was conducted by Health Canada scientists in 2013 on *C. utilis* ATCC 9950 and clinically significant *Candida* species using publicly available *Candida* 18S and 28S rRNA gene sequences and on *C. utilis* ATCC 9950 sequences generated in-house. The resulting dendrogram (Figure 1-2) demonstrates the divergence between *C. utilis* ATCC 9950 and pathogenic *Candida* species, such as *C. albicans*, *C. dubliniensis*, *C. tropicalis*, and *C. parapsilosis*, and to a lesser extent *C. glabrata*. This finding is consistent with others reported in the scientific literature (Buerth et al. 2011; Tomita et al. 2012).




Figure 0-2: Phylogenetic analysis of select *Candida* species based on the alignment of the ITS1 and ITS2 sequences of the 18S and 28S rRNA genes

The genome of *C. utilis* ATCC 9950 was sequenced by Buerth et al. (2011) and Tomita et al. (2012). The genomic composition determined from the shotgun sequence determined by Tomita et al.(2012) is summarized in Table 1-3.

Table 0-3: Molecular properties of *C. utilis* ATCC 9950 predicted from shotgun sequences

Characteristic	<i>C. utilis</i> ATCC 9950 ^a
Genome size	14.6 Mb
Predicted number of genes	8864
Assembled chromosomes	13
Unmapped chromosomes	1
G+C content (%)	45.36
Coding (%)	59.2
tRNA genes	191
rRNA genes	27
Ploidy	Tetraploid
Genomic Sequence Accession Numbers	BAEL01000001 – BAEL01001163

^a Adapted from Tomita et al. (2012)

The large subunit (LSU) D2 rDNA and ITS1-5.8S rDNA-ITS2 regions from *C. utilis* ATCC 9950 were sequenced by Health Canada researchers based on methods by Chen et al. (2000) and Ciardo et al. (2006) and were used as query sequences against the fungal database of the Applied BioSystems Microseq and the DNA databases of the National Center for Biotechnology Information (NCBI) using the

Basic Local Alignment Search Tool (BLAST). Using the LSU D2 region sequence for comparison in the Microseq database, *C. utilis* ATCC 9950 is 99.8% homologous to its teleomorph *Pichia jadinii* (type strain ATCC 18201). NCBI BLAST sequence alignments of the ITS1-5.8S rDNA-ITS2 region show 95% and 100% rDNA homology to *P. jadinii* type strain.

Other molecular techniques that can be used to complement phenotypic methods and to reliably distinguish closely-related *Candida* species include:

- o PCR assay using universal fungal primers and species-specific probes targeting the ITS2 region (Elie et al. 1998)
- o 18S rRNA sequencing from species with characteristic phenotypes, such as the production of ubiquinone (Suzuki and Nakase 2002)
- o multilocus sequence typing (MLST) of housekeeping genes (reviewed in Spampinato and Leonardi 2013; Bounoux et al. 2004; Odds and Jacobsen 2008; Tavanti et al. 2005)
- o microsatellite length polymorphism of short tandem repeats (Botterel et al. 2001; Enache-Angoulvant et al. 2010; Garcia-Hermoso et al. 2010; L'Ollivier et al. 2012; Tavanti et al. 2003)

Currently published methods do not permit distinction between different *C. utilis* strains.

1.2 Biological and ecological properties

1.2.1 Natural occurrence

Environmental strains of *C. utilis* have been isolated from various geographic locations and habitats including:

- o phyllosphere of the halophyte *Halocnemum strobilaceum* (type of shrub) in the southern coast of Kuwait (Al-Mailem et al. 2010),
- o soil (Atuanya and Oseghe 2006; Pan et al. 2009; Zheng et al. 2001),
- o eutrophic lakes in Olsztyn, Poland from a depth of up to 30 cm and 4.5 m away from the shore (Biedunkiewicz et al. 2013),
- o air (Pisman and Somova 2003)
- o water from melted icicles in north-eastern Poland (Biedunkiewicz and Ejdys 2011),
- o deep well in Qena, Egypt (Mohawed 1994),
- o hydrophyte wastewater treatment plant in Nowa Słupia, Poland (Biedunkiewicz and Ozimek 2009),
- o landfill leachate, activated sludge flocs and in sewage treatment batch reactor outflow in Poland (Szyłak-Szydlowski and Kornilowicz-Kowalska 2012), and
- o wastewater from cassava processing plants in Nigeria (Arotupin 2007).

Occurrence of other *Candida* species, such as *C. albicans*, *C. glabrata*, *C. guilliermondii*, *C. parapsilosis*, *C. tropicalis*, *C. solani* and *C. zeylanoides* in

aquatic habitats (i.e. fresh water, estuaries, marine water, sewage, and polluted water) was reported in the literature (Ahearn et al. 1968; Buck 1977; Buck and Bubucis 1978; Cook and Schlitzer 1981; reviewed in Jones and Schmitt 1978). Given that most *Candida species* are considered commensal gut yeasts in humans, it has been speculated that their isolation from aquatic environments likely results from contamination with human or animal excrement (Ahearn et al. 1968).

A soil persistence study on *C. utilis* ATCC 9950 undertaken by Environment Canada in 2005 used strain specific non-coding amplified fragment length polymorphism to estimate changes in concentration of the micro-organism. The study showed that if released into soil at an initial density of 10^4 CFU/g soil, the *C. utilis* ATCC 9950 population increases within 15 days to a density of 10^6 CFU/g soil. The population persists for up to 42 days, then declines to concentrations below the detection limit of 10^3 CFU/g soil (Figure 1-3) (personal communication, Beaudette 2014).




Figure 0-3: Persistence of *C. utilis* ATCC 9950, based on qPCR analyses of extractable soil DNA

1.2.2 Growth conditions

C. utilis is a facultative anaerobe. On sugars, fermentation occurs only under anaerobic conditions and growth is slow (Kurtzman et al. 1979; Visser et al. 1990; Franzblau and Sinclair 1983; Ordaz et al. 2001; Weusthuis et al. 1994). Under aerobic conditions, no accumulation of ethanol is observed (referred to as the Crabtree-effect) (Kaliterna et al. 1995; Tomita et al. 2012).

C. utilis ATCC 9950 has a growth temperature range of 10°C to 39°C with optimal growth observed at 35°C (NCYC 2014). Growth kinetics of *C. utilis* ATCC 9950 on various growth media at different temperatures was conducted at Health Canada and is shown in Appendix A Table A-1.

C. utilis is adaptable to a wide range of substrates and conditions. It thrives in environments that are rich in sugars such as xylose, hexose and pentose (Buerth et al. 2011; Chakravorty et al. 1962; Chang 1985; Kurtzman et al. 1979; Lee and Kyun

Kim 2001). *C. utilis*, including ATCC 9950, is generally cultivated on by-products containing free sugars, such as wastes from food and beverage manufacturing (Gold et al. 1981).

C. utilis also grows on organic acids and alcohols. Diauxic growth pattern was observed on *C. utilis* strain CBS621 on mixtures of sugars and ethanol (Weusthuis et al. 1994). During growth on glucose and ethanol, both substrates are utilized simultaneously, but when the yeast is provided with mixtures of maltose and ethanol, the latter substrate is preferentially utilized.

The organism thrives on media supplemented with nitrogen compounds, such as urea, ammonium salts, pyrimidine, and various amino acids (Buerth et al. 2011). *C. utilis* also grows well in sulfur-rich environments. When cultivated for single-cell protein biomass, *C. utilis* is often grown in sulfite liquor generated from pulp and paper processing (Gold et al. 1981; Streit et al. 1987).

Certain strains of *C. utilis* can grow on a wide range of aliphatic and aromatic hydrocarbons as sole sources of carbon and energy (Al-Mailem et al. 2010).

C. utilis strains that have been used in industrial fermentation processes have been exposed to fluctuations in temperature, oxygen concentration, osmotic pressure, pH, nutrient availability and salts. The following examples illustrate the extent to which *C. utilis* strains tolerate fluctuations in different parameters:

- o Viability of *C. utilis* strain RD898 decreased with increasing osmotic pressure, where 15-26 MPa osmotic pressure caused a loss of 40% of the population at 22°C (Mille et al. 2005);
- o *C. utilis* strain HP-P1 grew well in salinities between 1 to 2M NaCl, but did not tolerate salinities greater than 2M NaCl (Al-Mailem et al. 2010);
- o *C. utilis* strain WSH 02–08 was not affected by extremes in pH from 5.5 to 10.5 (Nie et al. 2005). *C. utilis* ATCC 60459 tolerated temperatures up to 50°C when a circadian-like rhythm of the light-dark cycle is in place; survival was markedly decreased in constant darkness (Lapena et al. 2006). The authors speculated that the transient development of resistance to various stresses for this strain under the stationary growth phase was in response to light-induced generation of reactive oxygen species; and
- o Metabolism of *C. utilis* ATCC 60560 was affected relatively quickly following a 15 minute interruption of air supply (Vraná and Sobotka 1989).

1.2.3 Nutrient cycling

Nitrate assimilation is a unique characteristic of *C. utilis* (Tomita et al. 2012). The *C. utilis* ATCC 9950 genome sequence revealed the existence of a contiguous nitrate/nitrite assimilation gene cluster which is considered to be responsible for the nitrate assimilation phenotype in *C. utilis* (Tomita et al. 2012).

C. utilis strain F87 can control eutrophication by converting nutrients such as nitrogen and phosphorus into microbial protein, simultaneously inhibiting the growth of the algae *Microcystis aeruginosa* (Kong et al. 2013). The authors showed that *C. utilis* strain F87 was better able to absorb ammonia nitrogen and phosphorus than *M. aeruginosa* in water, and the growth of *M. aeruginosa* was inhibited due to the lack of nutrients.

1.2.4 Biocontrol

Various *C. utilis* strains have antibacterial and antifungal properties that are expressed either through the secretion of enzymes or interaction with other micro-organisms:

- o *C. utilis* strain PYCC 3671 showed potential “killer phenotype” against a variety of *Candida* and non-*Candida* species (Antunes and Aguiar 2012);
- o When used to ferment the biomass of *Ecklonia cava* (brown algae), *C. utilis* strain KCTC 11355 exhibited an antibiotic property against methicillin-resistant *Staphylococcus aureus* (Eom et al. 2013);
- o *C. utilis* strain TISTR 5001, in combination with plant extracts, was used as a fungicide against post-harvest green mold rot on tangerines caused by *Penicillium digitatum* (Sukorinia et al. 2013);
- o At a concentration of 10^8 CFU/mL, *C. utilis* strain MPPLY-001 alone or in combination with chitosan effectively controlled tomato fruit rot caused by *Alternaria alternata* and *Geotrichum candidum* (Sharma et al. 2006);
- o A consortium containing *C. utilis* was found to inhibit fire blight disease caused by *Erwinia amylovora* in apples (Martinez et al. 2008);
- o Certain strains of *C. utilis* have been utilized as biocontrol agents against post-harvest bacterial and fungal pathogens in citrus fruits (Sukorinia et al. 2013), tomatoes (Sharma et al. 2006), and apples (Martinez et al. 2008).
- o *C. utilis* acted as a probiotic, enhancing protection against pathogenic bacteria *Pasteurella haemolytica* and *Vibrio alginolyticus* for *Artemia nauplii* (brine shrimp) larvae (Abdelkarim et al. 2010); and
- o *C. utilis* provided moderate protection to rainbow trout against the fish pathogen *Aeromonas salmonicida* (Siwicki et al. 1994).

A consortium containing bacteria and fungi, including *C. utilis*, has been shown to promote growth on hydroponic *Lolium perenne* L. (turf grass), as well as to reduce tearing out of the grass (Gaggia et al. 2013).

1.2.5 Biosorption of metals

The capacity of naturally-occurring strains of *C. utilis* to adsorb certain metals has been investigated. A few examples are listed below:

- o *C. utilis* ATCC 9950 adsorbed 5.42 mg magnesium/g dry cell mass (Blazejak et al. 2008) and 181.7 mg of zinc/g dry cell mass (Ahmad et al. 2013);

- o *C. utilis* strain RIBM C8 adsorbed cadmium 8.7 mg/g dry cell mass at pH 5.4 and 28 mg/g dry cell mass at pH 5.5 (Kujan et al. 2006);
- o Intact and dehydrated *C. utilis* cells were utilized to uptake hexavalent chromium from an aqueous solution in the presence of other metals (Muter et al. 2002); and
- o Failla et al. (1976) demonstrated the presence of a highly specific zinc ion transporter in *C. utilis* strain NRRL-Y-7634, which allows for the uptake, solubilization, transport and storage of zinc ions from the environment.

1.2.6 Susceptibility to chemical agents and antifungals

Certain strains of *C. utilis* are susceptible to acriflavine (Keyhani et al. 2009), and agricultural fungicides such as cymoxanil, penconazol, and dichlofluanid (Ribeiro et al. 2000).

Susceptibility of other *Candida* species to chemical disinfectants has been reported in the literature. Jones and Schmitt (1978) investigated the effect of chlorination on the survival of *C. albicans*. A cell concentration of 10^5 CFU/mL exposed to 2 ppm chlorine with a 30 minute contact period was reduced 10^1 CFU/mL, and 4, 8, 16, and 25-ppm treatments were lethal. *C. albicans* is also susceptible to quaternary ammonium compounds, such as benzalkonium chloride and cetrimide (Gupta et al. 2002; reviewed in McDonnell and Russell 1999). Moreover, *C. albicans* is susceptible to ozone, a gas commonly used in purification of drinking water, at an average concentration of 0.064 mg O₃/L (Restaino et al. 1995).

Antifungal susceptibility patterns of *C. utilis* isolated from clinical specimens indicate that *C. utilis* is susceptible to echinocandins (caspofungin, micafungin), triazoles (itraconazole, fluconazole, voriconazole, ketoconazole, posaconazole), and amphotericin B (Fleck et al. 2007; Pfaller et al. 2011; Tortorano et al. 2004). As shown in Table 1-4, antibiotic susceptibility testing conducted by Health Canada in 2013 indicates that *C. utilis* ATCC 9950 is susceptible to amphotericin B, nystatin, clotrimazole, isoconazole, micafungin, terbinafine, and 5-fluorocytosine + amphotericin B, which is consistent with the findings in the literature for the treatment of *Candida* infections.

Table 0-4: Minimal inhibitory concentrations of antifungal agents for *C. utilis* ATCC 9950

Antifungal	MIC (µg/mL) ^a
Amphotericin B	4.5 ± 1.7
Nystatin	3.8 ± 1.5
5-Fluorocytosine	>24
5-Fluorocytosine + Amphotericin B	1.1 ± 0.4
Clotrimazole	1.1 ± 0.4
Isoconazole	0.75
Intraconazole	15 ± 6
Micafungin	0.37

Terbinafine	1.3 ± 0.4
Griseofulvin	>24

^a Data generated by Health Canada's Environmental Health Science and Research Bureau

1.2.7 Pathogenic and toxigenic properties

C. utilis has relatively low virulence compared to pathogenic species of *Candida*, presumably because it lacks one or more of the virulence factors described below that contribute to the pathogenicity of *C. albicans*.

Morphogenesis

Morphogenesis (switching from cellular to hyphal to filamentous growth forms, and switching between opaque and white cell and colony phenotypes) is an important part of the pathogenic life cycle of *C. albicans* (Nadeem et al. 2013; Nie et al. 2010; Ramírez-Zavala et al. 2008; Vylkova et al. 2011; Whiteway and Bachewich 2007). An extensive search of the scientific literature provided no evidence to suggest that *C. utilis* can undergo morphogenesis, either from white to opaque phenotype or from cellular to hyphal growth.

Adherence

In *C. albicans*, adherence to host endothelial and epithelial cells is mediated by a range of cell wall glycoproteins (Hoyer 2001; Kinneberg et al. 1999; Staab et al. 1996). These surface adhesins also contribute to fungal antigenic variation (Liu and Filler 2011) and formation of biofilms (Nobile et al. 2008). *C. utilis* may share some glycoproteins with *C. albicans*, as there is antigenic cross-reactivity between the hyphal wall protein of *C. albicans* and *C. utilis* (Laín et al. 2007); however, in general these glycoproteins are specific to *C. albicans* based on antigenic specificity.

Quorum Sensing

Quorum sensing molecules, such as farnesol and tyrosol, are involved in regulating virulence in *C. albicans* (Cremer et al. 1999; Westwater et al. 2005). An extensive search of the scientific literature provided no evidence to suggest that *C. utilis* ATCC 9950 produces these quorum sensing molecules.

Biofilm

C. utilis forms biofilms in clinical settings. Paulitsch et al. (2009) reported that *C. utilis* was recovered from 1% of indwelling devices collected from intensive care units in Austria. Using scanning electron microscopy, the isolated *C. utilis* cells were described to be in an early stage of biofilm formation (i.e. mainly yeast cells in a basal layer). *In vitro* biofilm formation by a clinical isolate of *C. utilis* was enhanced in the presence of heparin preservative in the culture medium (Sabouraud Dextrose Broth at 37°C for 6 h; while EDTA was shown to reduce *C. utilis* biofilm formation (Al Akeel et al. 2013). Biofilms are relevant to pathogenicity because they exhibit increased drug resistance relative to planktonic cells and can seed bloodstream

infections that result in life-threatening systemic disease (reviewed in Finkel and Mitchell 2010).

Proteolytic enzymes and phospholipases

Production of proteolytic enzymes, such as aspartic protease (Sap), is considered crucial for *C. albicans* to cause epithelial tissue damage, tissue penetration during disseminated infection, and evasion and destruction of macrophages (Albrecht et al. 2006; reviewed in Gropp et al. 2009; Hube and Naglik, 2001; Naglik et al. 2004; Schaller et al. 1999). These enzymes are also associated with hyphal formation and phenotypic switching (Naglik et al. 2003). Aspartic proteases were not detected in *C. utilis* ATCC 9950 (Buerth et al. 2011). In *C. albicans*, extracellular phospholipases have been linked to adherence and membrane disruption during host cell invasion (Barrett-Bee et al. 1985; Ibrahim et al. 1995; Leidich et al. 1998). An extracellular phospholipase B has been identified in *C. utilis* (Fujino et al. 2006; Buerth et al. 2011).

Antimicrobial resistance

Induction of efflux pumps, encoded by the transporter genes *cdr1*, *cdr2*, and *mdr1*, has have been implicated in azole resistance in *Candida albicans* (Franz et al. 1998; Prasad et al. 1995; Riggle and Kumamoto 2006; Sanglard et al. 1997; Wirsching et al. 2000). Up-regulation of these genes in *C. albicans* biofilms has been related to intrinsic resistance of sessile cells to fluconazole compared with planktonic cells (Ramage et al. 2002). An extensive search of the scientific literature provided no evidence to suggest that the genome of *C. utilis* ATCC 9950 contains genes that have been associated with antimicrobial resistance.

Others

C. utilis ATCC 9950 is a tetraploid yeast (Ikushima et al. 2009; Tomita et al. 2012). In the mouse model of infection, *C. albicans* tetraploids were reported to be less virulent than diploids, either because they are inherently less able to survive host defenses, or may be outcompeted by the parental diploids, or they rapidly return to the diploid state via random chromosome loss (Ibrahim et al. 2005; Bennett and Johnson 2003).

The ability to grow optimally at normal human body temperature (37°C) and pH and to thrive at febrile temperatures also contributes to the incidence of *C. albicans* infections in humans. Generally, prolific hyphal growth requires a temperature of 37°C (reviewed in Sudbery 2011; Heilmann et al. 2011). Although *C. utilis* ATCC 9950 can grow at temperatures up to 39°C, its optimal growth is reported to be at 35°C.

A pH of 7.4 was found to be best suited for hyphal induction *in vitro* (Nadeem et al. 2013). Nonetheless, *C. albicans* is known to colonize and infect anatomical sites of diverse pH, including the mildly acidic mouth, skin and vagina, neutral intestine and blood, and highly acidic stomach (reviewed in Davis 2003; Vylkova et al. 2011).

In vitro and *in vivo* tests conducted on *C. utilis* ATCC 9950 at Health Canada found:

- o minimal cytotoxic effects on HT29 human colonic epithelial cells and J774A.1 macrophages after 2, 4 and 6 h of exposure to *C. utilis* ATCC 9950 with decreased cytotoxicity after 24 h;
- o no hemolytic activity on sheep blood agar after 48 h at 28°C and 37°C;
- o in four BALB/c mice per treatment, 1.0×10^6 CFU/25 µL exposed by endotracheal instillation showed, no changes in behaviour or physical appearance over a one week monitoring period, no significant increase in lung granulocytes and pro-inflammatory cytokines, or blood cytokine marker levels one week after exposure; and rapid clearance of *C. utilis* ATCC 9950 from the lungs, with dramatically reduced fungal cell numbers after 2 h and no yeast cells detected one week post exposure.

1.3 Effects

1.3.1 Environment

No reports have been specifically attributed to the DSL strain *C. utilis* ATCC 9950 in the scientific literature. Nonetheless, there have been rare reports of naturally-occurring infection in terrestrial mammals with other strains of *C. utilis*.

Plants

No reports in the literature implicate *C. utilis* in adverse effects in terrestrial or aquatic plants.

Certain strains of *C. utilis* have been used as biocontrol agents against disease-causing agents in plants (Section 1.2.4) without adverse effect in treated plants, which further supports its non-pathogenic nature in plants.

Invertebrates

No reports in the literature implicate *C. utilis* in adverse effects in terrestrial or aquatic invertebrates. Instead,

- o Lehner (1983) found that *C. utilis* is a suitable pollen substitute in the diets of *Apis mellifera* (honeybees). In a similar study, an increase in bee population was observed in colonies fed with the yeast (Peng et al. 1984);
- o *C. utilis* has been used successfully either as a feed supplement or as algae substitutes in the diets of Sydney rock oysters (Brown et al. 1996; Nell 1985; Nell et al. 1996) and American oysters (Epifanio 1979; Urban and Langdon 1984) with no adverse effects reported; and
- o live and freeze-dried *C. utilis* was successfully used as alternative food source for *Penaeus japonicus* (penaeid shrimp) with no adverse effect on growth or survival (Rahman 1996).

Vertebrates

No adverse effects on fish were attributed to *C. utilis* in the following feeding studies. Instead,

- o substitution of animal protein with 30% inactive *C. utilis* in the diet of *Oreochromis mossambicus* Peters (tilapia) and *Salmo salar* (Atlantic salmon) pre-smolts (Olvera-Novoa et al. 2002; Øverland et al. 2013) enhanced growth;
- o likewise, *C. utilis* protein supplement in the diet of Atlantic salmon counteracted intestinal inflammation arising from the conventional diet containing extracted soybean meal (Grammes et al. 2013);
- o Al-Hafedh and Alam (2013) reported that crude protein from *C. utilis* could also be used to replace fishmeal in Nile tilapia fingerlings without adverse effect on fish growth performance or feed utilization;
- o *C. utilis* (viability unknown) was found to be a suitable feed for *Cyprinus carpio* (carp) larvae, either alone or in combination with fish meal (Hecht and Viljoen 1982);
- o in *Oncorhynchus mykiss* (rainbow trout), diet supplemented with dried *C. utilis* stimulated growth and improved feed conversion rate (Stevens and Truog 1957);
- o similarly, Martin et al. (1993) deemed dried *C. utilis* a good substitute for traditional sources of protein in rainbow trout; and
- o diet containing dried *C. utilis* resulted in immunostimulation in rainbow trout and protection against *Aeromonas salmonicida* (Siwicki et al. 1994).

In the following feeding studies on poultry, swine and cattle no adverse effects were observed due to the presence of dried *C. utilis* in the diet. Instead,

- o chickens exposed to diet supplemented with probiotics containing *C. utilis*, *Bacillus subtilis* and *Lactobacillus acidophilus* in drinking water at 4.0×10^9 CFU/chicken/day for three days showed enhanced intestinal mucosal immune response up to 10 days post-exposure (Yurong et al. 2005);
- o Rodríguez et al. (2013) reported that *C. utilis* was effectively used to replace 20% of the soybean meal protein in broiler chicken diet;
- o *C. utilis* was used as protein substitute for up to 66% of total protein in pig feed for 8 days with no effect on weight or feed conversion (Mora et al. 2012);
- o bulls exposed to an herb diet supplemented with *Saccharomyces cerevisiae* and 15×10^{11} CFU *C. utilis*/g feed showed an increase in body weight (Mahyuddin and Winugroho 2010); and
- o one study reported that as a feed additive, the purified *C. utilis* cell wall elicited an immune response in germ-free piglets following a 54-day feeding experiment (Fencl et al. 1982). Histological analyses indicate an increase in immunoglobulin levels resulting from the stimulation of intestinal lymphatic apparatus of the jejunum and colon. Nevertheless, the animals were in good clinical condition throughout the study.

In a 4-week mouse study, Uetsuka et al. (1976) reported no mortalities in 80 mice dosed intravenously with 2.0×10^8 CFU/mL *C. utilis* strain FO-0639. Eight of the 40 mice had mild pyelitis, while three developed encephalitis.

In fifteen cortisone-treated (immunosuppressed) and untreated female Swiss Webster mice exposed intravenously to 1.0×10^7 CFU *C. utilis* strain ATCC 20248, no evidence of hyphae formation, inflammatory response, or tissue invasion, and no deaths were observed during the 30-day study (Holzschu et al. 1979). *C. utilis* at concentrations of 10^4 - 10^6 CFU/g tissue was recovered from the brain of mice sacrificed at day 6. Histopathological examination at day 30 showed persistence of the fungus in the kidney of the cortisone-treated mice (density of 1.70×10^3 CFU/g), but no signs of renal infection were observed. The authors considered that the recovery of residual fungus from the brains of mice sacrificed at day 6 was a function of the inoculation route rather than a neurotropic effect. The large volume of blood directed anteriorly from the heart could have carried the yeast to the brain where they may have been mechanically trapped in small vessels.

Two cases of arthritic joint infection caused by *C. utilis* in horses have been reported. *C. utilis* was isolated from synovial fluid samples of a three-year-old Standard bred filly with a history of bacterial infectious arthritis (Cohen et al. 2008). *C. utilis* infection was effectively treated with the combination of fluconazole, amphotericin B, and arthroscopic debridement. Hepworth (2012) reported a case of equine septic arthritis due to *C. utilis*. As with the previous case, the horse had a history of joint problems and had received corticosteroid treatments. *C. utilis* was also cultured from synovial fluid samples. The fungal infection was effectively treated with fluconazole. Cohen et al. (2008) attributed the ability of *C. utilis* to thrive in the joint, an area generally considered inhospitable for fungal growth, to the combination of antibiotics and local immune suppression with corticosteroid from previous treatments.

C. utilis has been sporadically isolated from cows with mastitis. A strain of *C. utilis* was isolated among other bacteria and yeasts (2.4% of total microbial load) from infected cows in Turkey (Turkylmaz and Kaynarca 2010). Similarly, Wawron et al. (2010) reported that *C. utilis* was the least common yeast isolated from infected udder secretions of cows in Poland, comprising of only 0.67% (1 of 150 isolated species). However, unlike other *Candida* species, such as *C. krusei*, *C. albicans*,

C. guilliermundi, *C. kefyr* and *C. rugosa*, *C. utilis* has not been implicated as an etiological agent of bovine mastitis (Costa et al. 1993; dos Santos and Marin 2005; Farnsworth and Sorensen 1972; Şeker 2010; Watts 1988; Zhou et al. 2013). Infections are often attributed to poor animal hygiene, the excessive and erratic use of antimicrobials and immunosuppressive drugs, and presence of other chronic diseases (reviewed in Watts 1988).

1.3.2 Humans

Among all the *Candida* species, *C. albicans*, *C. glabrata*, *C. tropicalis* and *C. parapsilosis* together account for approximately 95% identifiable *Candida*

infections (reviewed in Butler et al. 2009). Other species, including *C. krusei*, *C. lusitanae*, and *C. guilliermondii*, account for less than 5% of invasive candidiasis (reviewed in Butler et al. 2009).

C. utilis is generally not considered as an etiological agent of infection in humans, but it has occasionally been isolated from clinical samples. Based on epidemiological surveys conducted worldwide and on reported cases, the clinical isolation of *C. utilis* is rare (Lyon et al. 2010; Montagna et al. 2014; Oberoi et al. 2012; Odds et al. 2007; Paulitsch et al. 2006; Pfaller et al. 2011; Presterl et al. 2007; Tortorano et al. 2004). *C. utilis* has been recovered from patients' blood, alimentary tract, urine, mouth, feces and cervix (Alsina et al. 1988; Dorko et al. 2000; Hazen et al. 1999; Lyon et al. 2010; Song et al. 2009).

The incidence of *C. utilis* infection is low. It has been linked to a few cases of candidemia in neonates, and individuals who have undergone invasive medical procedures or with existing health conditions (González et al. 2008; Lukic-Grlić et al. 2011; Luzzati et al. 2013; Montagna et al. 2014; Pfaller et al. 2012; Pfaller et al. 2011; Presterl et al. 2007; Tortorano et al. 2004), including keratitis (Alkatan et al. 2012; Shih et al. 1999), urinary tract infection (Dorko and Pilipčinec, 2002; Hazen et al. 1999), vaginitis (Al Akeel et al. 2013), dental thrush (Song et al. 2009), and fungaemia (Dekeyser et al. 2003). Hospital-acquired *C. utilis* fungemia, attributed to contamination of indwelling medical devices, has also been reported (Alsina et al. 1988), while a rare case of fungemia in an immunocompetent (otherwise healthy) individual was also documented (Bougnoux et al. 1993).

No outbreaks related to *C. utilis* have been reported. *C. utilis* infections have rarely resulted in mortality. Deaths are often directly attributed to significant co-morbidities, rather than to the presence of *C. utilis* in the clinical material.

No cases of allergic reaction have been reported specifically for *C. utilis* ATCC 9950; however other strains of *C. utilis* have been linked to sensitization amongst atopic individuals (up to 35% of this sub-population) (Koivikko et al. 1988).

- o *C. utilis* shares common antigens with *C. albicans* and multiple concurrent sensitization to extracts of several *Candida* sp. including *C. utilis*, has been reported in atopic patients, suggesting the possible presence of one or more common skin reactive allergens (Koivikko et al. 1988). The theoretical implication is that persons previously sensitized to *C. albicans* are likely to experience elicitation reactions when exposed to *C. utilis* antigens; and
- o Sensitization to feed dusts containing *C. utilis* antigens was reported among swine workers with five to ten years' experience in swine production in Finland (Katila et al. 1981). Respiratory symptoms include coughing and dyspnoea.

1.4 Hazard severity

A combination of morphological, biochemical, and molecular traits allows *C. utilis* to be reliably discriminated from other *Candida* species, especially closely-related

pathogens such as *C. albicans*.

Information from the scientific literature suggests that neither *C. utilis*, nor its teleomorph *Pichia jadinii*, is a frank pathogen towards environmental species. There is no evidence to suggest that *C. utilis* has adversely affected terrestrial or aquatic invertebrates, plants or vertebrates. *C. utilis* has an established history of safe use as a feed supplement, either in live or inactive form, in aquaculture, swine, poultry, and livestock diets. Results from pathogenicity testing on mice also indicate that *C. utilis* does not cause adverse effects. Only two incidents of secondary infections (not experimentally-induced) were attributed to *C. utilis* and, in both cases, the animals had pre-existing conditions and the infections were effectively treated with antifungals. Thus, the environmental hazard severity for *C. utilis* ATCC 9950 is estimated to be low.

No human infections have been specifically attributed to the DSL strain *C. utilis* ATCC 9950 in the scientific literature. Despite its long history of use in food production worldwide, there have only been a few cases of infection associated with exposure to *C. utilis*. These include reports of secondary infection in individuals with predisposing factors such as compromised immunity. In most cases, the infections were effectively treated with antifungals. The human hazard severity for *C. utilis* ATCC 9950 is therefore estimated to be low.

Hazards related to micro-organisms used in the workplace should be classified accordingly under the Workplace Hazardous Materials Information System (WHMIS)⁴.

Exposure Assessment

2.1 Sources of exposure

The focus of this assessment is to characterize the exposure to *C. utilis* ATCC 9950 from its deliberate addition to consumer or commercial products or its use in industrial processes in Canada.

C. utilis ATCC 9950 was nominated to the DSL in 1997 for its use in the production of food products. Responses to a 2007 voluntary questionnaire sent to a subset of key biotechnology companies in Canada, combined with information obtained from other federal government regulatory and non-regulatory programs, did not indicate that *C. utilis* ATCC 9950 was imported into Canada in the 2006 calendar year.

⁴ A determination of whether one or more of the criteria of section 64 of CEPA 1999 are met is based upon an assessment of potential risks to the environment and/or to human health associated with exposure in the general environment. For humans, this includes, but is not limited to, exposure from air, water and the use of products containing the substances. A conclusion under CEPA 1999 on *C. utilis* ATCC 9950 is not relevant to, nor does it preclude, an assessment against the hazard criteria for WHMIS that are specified in the *Controlled Products Regulations* for products intended for workplace use.

The Government conducted a mandatory information-gathering survey under section 71 of CEPA 1999 (hereafter referred to as the section 71 Notice), as published in the *Canada Gazette* Part I on October 3, 2009. The section 71 Notice applied to any persons who, during the 2008 calendar year, manufactured or imported *C. utilis* ATCC 9950, whether alone, in a mixture, or in a product. Responses to the section 71 Notice indicate that approximately 80 metric tonnes of *C. utilis* ATCC 9950 (viability, formulation and concentration unknown) were imported into Canada for the production and processing of food during the 2008 reporting year. *C. utilis* used as a flavour enhancer or dietary supplement is commonly in inactive form (non-living). Although the section 71 Notice was intended to gather information about living organisms, it seems likely (given the uses and quantities reported) that the respondents may have included inactive *C. utilis* ATCC 9950 in their responses to the survey. The exposure assessment will only consider exposure to living *C. utilis* ATCC 9950.

C. utilis ATCC 9950 is available for purchase from the ATCC. As it is on the DSL, and so can be used in Canada without prior notification, it could be an attractive choice for commercialization. As mentioned in sections 1.2.4 and 1.3.1, *C. utilis* has properties that allow it to act as a potential biocontrol agent, to be used in fish and animal feed, and as a growth promoter in animals (i.e. probiotic, supplement). Similarly, *C. utilis* ATCC 9950 and other naturally-occurring strains of *C. utilis* have been widely used in the food industry since the mid-1940s, particularly as a flavouring agent in processed foods (inactive form) and as probiotics (Kurtzman et al. 1979). These products are commonly marketed as Dried Torula Yeast, Torula Yeast, or Yeast Torula. A few representative examples are listed below:

- o autolyzed yeast or inactive dried yeast for processing and production (emulsification, texture and flavour enhancement) of beverages and food (Product Sheets, 2014a – d)
- o inactive dried yeast as a component of human dietary supplements (Product Sheets, 2014e, g-h).
- o active yeast in probiotics (Product Sheets, 2014f).

A search of the public domain indicates that other naturally-occurring strains of *C. utilis* are mainly used as production organisms for the following:

- o industrial biochemicals such as 4-hydroxybutyrate, 1,4-butanediol, L-phenylacetylcarbinol, and invertase (Belcarz et al. 2002; Khan and Daugulis, 2010; Pharkya et al. 2014)
- o cosmetic or pharmaceutical ingredients such as glutathione (Product Sheet, 2014i), lactic acid (Ikushima et al. 2010) and glucomannan (Ruszova et al. 2008)
- o bioethanol (Domenech et al. 1999).

Other potential uses identified from the literature and from patent submissions include, but are not limited to:

- o reduction of biological oxygen demand and lactic acid in waste effluents from food processing, alcoholic distillation, and pulp and paper processing (Gold et al. 1981; Hang, 1980; Lemmel et al. 1979; Oliva and Hang, 1979; Razif et al. 2006; SivaRaman et al. 1984; Stevenson et al. 1979)
- o wood processing and sugar production (Chesonis and Horton, 2014)
- o bioremediation of aflatoxins (El-Shiekh et al. 2007)
- o removal of gaseous ethanol in biofilters (Christen et al. 2002)
- o degradation of crude petroleum (Nwachukwu, 2000).

According to the Material Safety Data Sheets for some of the aforementioned uses, *C. utilis* is packaged as fine powder, pellets, flakes or pills.

2.2 Exposure characterization

2.2.1 Environment

The environmental exposure for *C. utilis* ATCC 9950 is estimated to be low to medium based on responses to the section 71 Notice in which reported uses were limited to use in human food production and processing.

C. utilis is metabolically versatile and is expected to readily adapt to various environments. It has been isolated from soil, water, air, and waste and wastewater under different conditions. As demonstrated in the persistence study commissioned by Environment Canada, *C. utilis* ATCC 9950 in microcosm soil can be detected for up to 42 days.

Exposure of terrestrial and aquatic invertebrates and vertebrates to viable *C. utilis* ATCC 9950 is expected to be greatest through the consumption of livestock probiotics used in agriculture and aquaculture. Residual *C. utilis* ATCC 9950 in soil and other surfaces from feed preparation could also result in dermal exposure to terrestrial vertebrates. Given that the livestock and aquaculture feeds are generally prepared using the inactive form of the yeast, exposure to live *C. utilis* ATCC 9950 through these sources is considered low.

Indirect exposure of environmental species to *C. utilis* ATCC 9950 through disposal of food wastes in municipal landfills or sewers is considered relatively insignificant given that the majority of foods containing *C. utilis* ATCC 9950 will likely contain the inactive form of the yeast.

The following exposure scenarios are based on potential uses of other *C. utilis* strains as described in Section 2.1 Sources of exposure. Uses, such as bioremediation and disposal of solid wastes from manufacturing facilities, are likely to introduce *C. utilis* ATCC 9950 to terrestrial ecosystems. Terrestrial invertebrates living in the soils at the site of application or disposal and plants growing in treated soils are likely to be the most directly exposed. Vertebrates could ingest *C. utilis* ATCC 9950 while feeding on plants or invertebrates growing in treated or contaminated soils.

Aquatic species may come into contact with *C. utilis* ATCC 9950 from runoff subsequent to terrestrial application or disposal of wastewater from facilities that use the organism for production of enzymes and biochemicals. Nonetheless, the release of *C. utilis* ATCC 9950 from these facilities is expected to be limited by the application of good manufacturing practices, in which measures should be taken to minimize the release of production micro-organisms. Also, the extent of exposure will depend on the mass or volume released, on the receiving environment, and on the proximity of environmental species to the sites of application or disposal.

2.2.2 Human

Based on commercial activity in Canada according to the section 71 Notice, and the considerations outlined below, the overall human exposure estimation for *C. utilis* ATCC 9950 is low.

Direct human exposure to live *C. utilis* ATCC 9950 is greatest through the consumption of dietary supplements or probiotics containing viable yeasts. Handling of food products containing *C. utilis* ATCC 9950 could result in skin and inhalation exposures; however, given that these food products are generally prepared using the inactive form of the yeast, exposure to viable *C. utilis* ATCC 9950 through these routes is considered relatively low.

Should other potential uses of *C. utilis* ATCC 9950 be realized in Canada, humans could be more exposed to *C. utilis* ATCC 9950 in the environment subsequent to its use in wastewater treatment, bioremediation, or from disposal of waste generated during the production of enzymes and biochemicals. The extent of this exposure would depend on the mode of use, the mass or volume applied, and proximity to the application or disposal site. Such exposures may be temporally distant from the time of release and are expected to be significantly lower relative to exposure to live yeasts in dietary supplements and probiotics. Furthermore, uses for enzyme and biochemical production in manufacturing facilities that do not release wastes into the environment should not result in human exposure.

In the event that the organism enters municipal drinking water treatment systems (through release from potential uses and from wastewater), treatment processes which include coagulation, flocculation, ozonation, filtration and chlorination are expected to effectively eliminate *C. utilis* ATCC 9950 from drinking water.

Risk Characterization

In this assessment, risk is characterized according to a paradigm whereby a hazard and exposure to that hazard are both required for there to be a risk. The risk assessment conclusion is based on the hazard and on what is known about exposure from current uses.

Hazard has been estimated for *C. utilis* ATCC 9950 to be low for both the environment and for human health. Based on responses to the section 71 Notice, the exposure to living *C. utilis* ATCC 9950 from its use in industrial processes, and

consumer or commercial applications in Canada is expected to be low to medium for both the environment and human health.

Owing to the low potential for hazard, the overall risk associated with current uses is estimated to be low for both the environment and human health.

The determination of risk from current uses is followed by consideration of the estimated hazard in relation to foreseeable future exposures (from new uses).

C. utilis ATCC 9950 has useful properties that make it of interest for use in bioremediation, and for the production of biochemicals. These uses could increase environmental and human exposure of this strain in the future. The risk from reasonably foreseeable uses of *C. utilis* ATCC 9950 remains low given that there is no evidence of adverse effects to human health or of adverse ecological effects at the population level for environmental species. This conclusion is also supported by the long history of safe use of *C. utilis* in industrial, environmental, and commercial settings.

Conclusion

Based on the information presented in this screening assessment, it is concluded that *C. utilis* ATCC 9950 is not entering the environment in a quantity or concentration or under conditions that:

- have or may have an immediate or long-term harmful effect in the environment or its biological diversity;
- constitute or may constitute a danger to the environment on which life depends; or
- constitute or may constitute a danger in Canada to human life or health.

Therefore, it is concluded that this substance does not meet the criteria as set out in section 64 of the CEPA 1999.

References

- Abdelkarim, M. Kamel, C. Fathi, K. and Amina, B. (2010). Use of *Pseudomonas stutzeri* and *Candida utilis* in the improvement of the conditions of *Artemia* culture and protection against pathogens. *Braz. J. Microbiol.* **41**, 107-115.
- Ahearn, D. Roth Jr, F. and Meyers, S. (1968). Ecology and characterization of yeasts from aquatic regions of South Florida. *Mar. Biol.* **1**, 291-308.
- Ahmad, M.F. Haydar, S. and Quraishi, T.A. (2013). Enhancement of biosorption of zinc ions from aqueous solution by immobilized *Candida utilis* and *Candida tropicalis* cells. *Int. Biodeterior. Biodegrad.* **83**, 119-128.
- Al Akeel, R.A. El Kersh, T.A. Al Sheikh, Y.A. and Al Ahmadey, Z.Z. (2013). Prevalence and comparison for detection methods of *Candida* species in vaginal specimens from pregnant and non pregnant Saudi women. *Afr. J. Microbiol. Res.* **7**, 56-65.
- Albrecht, A. Felk, A. Pichova, I. Naglik, J.R. Schaller, M. de Groot, P. Maccallum, D. Odds, F.C. Schafer, W. Klis, F. Monod, M. and Hube, B. (2006). Glycosylphosphatidylinositol-anchored proteases of *Candida albicans* target proteins necessary for both cellular processes and host-pathogen interactions. *J. Biol. Chem.* **281**, 688-694.
- Al-Hafedh, Y.S. and Alam, A. (2013). Replacement of fishmeal by single cell protein derived from yeast grown on date (*Phoenix dactylifera*) industry waste in the diet of Nile Tilapia (*Oreochromis niloticus*) fingerlings. *J. Appl. Aquac.* **25**, 346-358.
- Alkatan, H. Athmanathan, S. and Canites, C.C. (2012). Incidence and microbiological profile of mycotic keratitis in a tertiary care eye hospital: A retrospective analysis. *Saudi J. Ophthalmol.* **26**, 217-221.
- Al-Mailem, D. Sorkhoh, N. Marafie, M. Al-Awadhi, H. Eliyas, M. and Radwan, S. (2010). Oil phytoremediation potential of hypersaline coasts of the Arabian Gulf using rhizosphere technology. *Bioresour. Technol.* **101**, 5786-5792.
- Alsina, A. Mason, M. Uphoff, R.A. Riggsby, W.S. Becker, J.M. and Murphy, D. (1988). Catheter-associated *Candida utilis* fungemia in a patient with acquired immunodeficiency syndrome: species verification with a molecular probe. *J. Clin. Microbiol.* **26**, 621-624.
- Antunes, J. and Aguiar, C. (2012). Search for killer phenotypes with potential for biological control. *Ann. Microbiol.* **62**, 427-433.
- Arotupin, D.J. (2007). Evaluation of microorganisms from cassava waste water for production of amylase and cellulase. *Res. J. Microbiol.* **2**, 475-480.
- Atuanya, E.I. and Oseghe, E.O. (2006). Lead contamination and microbial lead tolerance in soils at major road junctions in Benin City. *J. Appl. Sci. Env. Manag.* **10**, 99-104.
- Barnett, J.A. (2004). A history of research on yeasts 8: Taxonomy. *Yeast* **21**, 1141-1193.
- Barnett, J.A. Payne, R.W. and Yarrow, D. (2000). Yeasts: characteristics and identification (Cambridge, U.K. ; New York, NY, USA: Cambridge University Press).
- Barrett-Bee, K. Hayes, Y. Wilson, R.G. and Ryley, J.F. (1985). A comparison of phospholipase activity, cellular adherence and pathogenicity of yeasts. *J. Gen. Microbiol.* **131**, e1217.

- Belcarz, A. Ginalska, G. Lobarzewski, J. and Penel, C. (2002). The novel non-glycosylated invertase from *Candida utilis* (the properties and the conditions of production and purification). *BBA-Protein Struct. M.* 1594, 40-53.
- Bennett, R.J. and Johnson, A.D. (2003). Completion of a parasexual cycle in *Candida albicans* by induced chromosome loss in tetraploid strains. *EMBO J.* 22, 2505–2515.
- Biedunkiewicz, A. Dynowska, M. Ejdy, E. and Sucharzewska, E. (2013). Species diversity of yeast-like fungi in some eutrophic lakes in Olsztyn. *Acta Mycol.* 48, 61-71.
- Biedunkiewicz, A. and Ejdy, E. (2011). Icicles as carriers of yeast-like fungi potentially pathogenic to human. *Aerobiologia* 27, 333-337.
- Biedunkiewicz, A. and Ozimek, T. (2009). Qualitative and quantitative changes of potentially pathogenic fungi in a hydrophyte wastewater treatment plant. *Pol. J. Environ. Stud.* 18, 161-166.
- Blazejak, S. Duszkiewicz-Reinhard, W. Gniewosz, M. and Wiatrzyk, P. (2008). Impact of magnesium and mannose in the cultivation media on the magnesium biosorption, the biomass yield and on the cell wall structure of *Candida utilis* yeast. *Eur. Food Res. Technol.* 227, 695-700.
- Botterel, F. Desterke, C. Costa, C. and Bretagne, S. (2001). Analysis of microsatellite markers of *Candida albicans* used for rapid typing. *J. Clin. Microbiol.* 39, 4076-4081.
- Bougnoux, M. Aanensen, D.M. Morand, S. Théraud, M. Spratt, B.G. and d'Enfert, C. (2004). Multilocus sequence typing of *Candida albicans*: strategies, data exchange and applications. *Infect. Genet. Evol.* 4, 243-252.
- Bougnoux, M.-. Gueho, E. and Potocka, A.-. (1993). Resolutive *Candida utilis* fungemia in a nonneutropenic patient. *J. Clin. Microbiol.* 31, 1644-1645.
- Brown, M.R. Barrett, S.M. Volkman, J.K. Nearhos, S.P. Nell, J.A. and Allan, G.L. (1996). Biochemical composition of new yeasts and bacteria evaluated as food for bivalve aquaculture. *Aquaculture* 143, 341-360.
- Buck, J.D. (1977). Comparison of in situ and in-vitro survival of *Candida albicans* in seawater. *Microb. Ecol.* 4, 291-302.
- Buck, J.D. and Bubucis, P.M. (1978). Membrane filter procedure for enumeration of *Candida albicans* in natural waters. *Appl. Environ. Microbiol.* 35, 237-242.
- Buerth, C. Heilmann, C.J. Klis, F.M. de Koster, C.G. Ernst, J.F. and Tielker, D. (2011). Growth-dependent secretome of *Candida utilis*. *Microbiology+* 157, 2493-2503.
- Butler, G. Rasmussen, M.D. Lin, M.F. Santos, M.A. Sakthikumar, S. Munro, C.A. Rheinbay, E. Grabherr, M. Forche, A. and Reedy, J.L. (2009). Evolution of pathogenicity and sexual reproduction in eight *Candida* genomes. *Nature* 459, 657-662.
- CBS-KNAW. (2014). CBS-KNAW Fungal Biodiversity Center Database. CBS 5609 Strain Information. <http://www.cbs.knaw.nl/Collections/BioloMICS.aspx?Table=CBS%20strain%20database&Rec=2440&Fields=All> (viewed June 2014).
- CFIA. (2014). Canadian Food Inspection Agency. Feeds Regulations 1983 (SORS/83-539). <http://laws-lois.justice.gc.ca/eng/regulations/SOR-83-593/page-17.html> (viewed March 2014).

- Chakravorty, M. Veiga, L.A. Bacila, M. and Horecker, B.L. (1962). Pentose metabolism in *Candida* . II. The diphosphopyridine nucleotide-specific polyol dehydrogenase of *Candida utilis*. J. Biol. Chem. 237, 1014-1020.
- Chang, F.H. (1985). Effects of some environmental factors on growth characteristics of *Candida utilis* on peat hydrolysates. Appl. Environ. Microbiol. 49, 54-60.
- Chen, Y.C. Eisner, J.D. Kattar, M.M. Rassouljian-Barrett, S.L. LaFe, K. Yarfitz, S.L. Limaye, A.P. and Cookson, B.T. (2000). Identification of medically important yeasts using PCR-based detection of DNA sequence polymorphisms in the internal transcribed spacer 2 region of the rRNA genes. J. Clin. Microbiol. 38, 2302-2310.
- Chesonis, A. and Horton, J.W. (2014). Integrated wood processing and sugar production. US 20140038244 A1.
- Christen, P. Domenech, F. Michelena, G. Auria, R. and Revah, S. (2002). Biofiltration of volatile ethanol using sugar cane bagasse inoculated with *Candida utilis*. J. Hazard. Mater. 89, 253-265.
- Ciardo, D.E. Schär, G. Böttger, E.C. Altwegg, M. and Bosshard, P.P. (2006). Internal transcribed spacer sequencing versus biochemical profiling for identification of medically important yeasts. J. Clin. Microbiol. 44, 77-84.
- Cohen, J.M. Ross, M.W. and Busschers, E. (2008). Diagnosis and management of *Candida utilis* infectious arthritis in a Standardbred filly. Equine Vet. Educ. 20, 348-352.
- Cook, W.L. and Schlitzer, R.L. (1981). Isolation of *Candida albicans* from freshwater and sewage. Appl. Environ. Microbiol. 41, 840-842.
- Costa, E. Gandra, C. Pires, M. Coutinho, S. Castilho, W. and Teixeira, C. (1993). Survey of bovine mycotic mastitis in dairy herds in the State of São Paulo, Brazil. Mycopathologia 124, 13-17.
- Cremer, J. Vatou, V. and Braveny, I. (1999). 2, 4-(Hydroxyphenyl)-ethanol, an antioxidative agent produced by *Candida* spp. impairs neutrophilic yeast killing in vitro. FEMS Microbiol. Lett. 170, 319-325.
- Davis, D. (2003). Adaptation to environmental pH in *Candida albicans* and its relation to pathogenesis. Curr. Genet. 44, 1-7.
- Dekeyser, S. Desmettre, T. Scala, L. Dufosse, M.-. Belletante, D. and Descamps, D. (2003). *Candida utilis* fungemia in an intensive care patient, resistant to treatment with fluconazole. Med. Mal. Infect. 33, 221-223.
- Domenech, F. Christen, P. Paca, J. and Revah, S. (1999). Ethanol utilization for metabolite production by *Candida utilis* strains in liquid medium. Acta Biotechnologica 19, 27-36.
- Dorko, E. and Pilipčinec, E. (2002). *Candida* I urinary tract infections caused by non-albicans *Candida* species. Folia Microbiol. (Praha) 47, 182-184.
- Dorko, E. Kmeťová, M. Pilipčinec, E. Bračoková, I. Dorko, F. Danko, J. Švický, E. and Tkáčiková, L. (2000). Rare non-albicans *Candida* species detected in different clinical diagnoses. Folia Microbiol. 45, 364-368.
- dos Santos, R.C. and Marin, J.M. (2005). Isolation of *Candida* spp. from mastitic bovine milk in Brazil. Mycopathologia 159, 251-253.

Elie, C.M. Lott, T.J. Reiss, E. and Morrison, C.J. (1998). Rapid identification of *Candida* species with species-specific DNA probes. J. Clin. Microbiol. 36, 3260-3265.

El-Shiekh, H.H. Mahdy, H.M. and El-Aaser, M.M. (2007). Bioremediation of aflatoxins by some reference fungal strains. Pol. J. Microbiol. 56, 215-223.

Enache-Angoulvant, A. Bourget, M. Brisse, S. Stockman-Pannier, C. Diancourt, L. Francois, N. Rimek, D. Fairhead, C. Poulain, D. and Hennequin, C. (2010). Multilocus microsatellite markers for molecular typing of *Candida glabrata*: application to analysis of genetic relationships between bloodstream and digestive system isolates. J. Clin. Microbiol. 48, 4028-4034.

Environment Canada, and Health Canada. (2011). Framework on the Science-Based Risk Assessment of Micro-organisms under the *Canadian Environmental Protection Act, 1999*. <http://www.ec.gc.ca/subsnouvelles-news/subs/default.asp?lang=En&n=120842D5-1>.

Eom, S. Lee, D. Kang, Y.M. Son, K. Jeon, Y. and Kim, Y. (2013). Application of yeast *Candida utilis* to ferment *Eisenia bicyclis* for enhanced antibacterial effect. Appl. Biochem. Biotechnol. 171, 569-582.

Epifanio, C.E. (1979). Comparison of yeast and algal diets for bivalve molluscs. Aquaculture 16, 187-192.

Failla, M.L. Benedict, C.D. and Weinberg, E.D. (1976). Accumulation and storage of Zn²⁺ by *Candida utilis*. J. Gen. Microbiol. 94, 23-36.

Farnsworth, R.J. and Sorensen, D.K. (1972). Prevalence and species distribution of yeast in mammary glands of dairy cows in Minnesota. Can. J. Comp. Med. 36, 329-332.

Fencel, Z. Tlaskalová-Hogenová, H. Machek, F. Kováru, F. Cerna, J. and Šillinger, V. (1982). Immunological changes after long-term feeding of germfree piglets with protein isolates and yeast cell walls from *Candida utilis* as food additives. Folia Microbiol 27, 350-353.

Finkel, J.S. and Mitchell, A.P. (2010). Genetic control of *Candida albicans* biofilm development. Nature Reviews Microbiology 9, 109-118.

Fleck, R. Dietz, A. and Hof, H. (2007). In vitro susceptibility of *Candida* species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest. J. Antimicrob. Chemother. 59, 767-771.

Franz, R. Kelly, S.L. Lamb, D.C. Kelly, D.E. Ruhnke, M. and Morschhauser, J. (1998). Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical *Candida albicans* strains. Antimicrob. Agents Chemother. 42, 3065-3072.

Franzblau, S.G. and Sinclair, N.A. (1983). Induction of fermentation in Crabtree-negative yeasts. Mycopathologia 82, 185-190.

Fricker-Hidalgo, H. Orenga, S. Lebeau, B. Pelloux, H. Brenier-Pinchart, M.P. Ambroise-Thomas, P. and Grillot, R. (2001). Evaluation of *Candida* ID, a new chromogenic medium for fungal isolation and preliminary identification of some yeast species. J. Clin. Microbiol. 39, 1647-1649.

Fujino, S. Akiyama, D. Akaboshi, S. Fujita, T. Watanabe, Y. and Tamai, Y. (2006) Purification and characterization of phospholipase B from *Candida utilis*. Biosci. Biotechnol. Biochem. 70, 377-386.

- Gaggia, F. Baffoni, L. Di Gioia, D. Accorsi, M. Bosi, S. Marotti, I. Biavati, B. and Dinelli, G. (2013). Inoculation with microorganisms of *Lolium perenne* L.: evaluation of plant growth parameters and endophytic colonization of roots. *New Biotechnol.* 30, 695-704.
- Garcia-Hermoso, D. MacCallum, D.M. Lott, T.J. Sampaio, P. Serna, M.J. Grenouillet, F. Klaassen, C.H. and Bretagne, S. (2010). Multicenter collaborative study for standardization of *Candida albicans* genotyping using a polymorphic microsatellite marker. *J. Clin. Microbiol.* 48, 2578-2581.
- Gold, D. Mohagheghi, A. Cooney, C.L. and Wang, D.I. (1981). Single-cell protein production from spent sulfite liquor utilizing cell-recycle and computer monitoring. *Biotechnol. Bioeng.* 23, 2105-2116.
- González, G.M. Elizondo, M. and Ayala, J. (2008). Trends in species distribution and susceptibility of bloodstream isolates of *Candida* collected in Monterrey, Mexico, to seven antifungal agents: Results of a 3-year (2004 to 2007) surveillance study. *J. Clin. Microbiol.* 46, 2902-2905.
- Grammes, F. Reveco, F.E. Romarheim, O.H. Landsverk, T. Mydland, L.T. and Øverland, M. (2013). *Candida utilis* and *Chlorella vulgaris* counteract intestinal inflammation in Atlantic Salmon (*Salmo salar* L.). *PloS One* 8, e83213.
- Gropp, K. Schild, L. Schindler, S. Hube, B. Zipfel, P.F. and Skerka, C. (2009). The yeast *Candida albicans* evades human complement attack by secretion of aspartic proteases. *Mol. Immunol.* 47, 465-475.
- Gupta, A.K. Ahmad, I. and Summerbell, R.C. (2002). Fungicidal activities of commonly used disinfectants and antifungal pharmaceutical spray preparations against clinical strains of *Aspergillus* and *Candida* species. *Med. Mycol.* 40, 201-208.
- Hang, Y.D. (1980). Assimilation of lemonade-processing wastewater by yeasts. *Appl. Environ. Microbiol.* 39, 470-472.
- Hata, D.J. Hall, L. Fothergill, A.W. Larone, D.H. and Wengenack, N.L. (2007). Multicenter evaluation of the new VITEK 2 advanced colorimetric yeast identification card. *J. Clin. Microbiol.* 45, 1087-1092.
- Hazen, K.C. Theisz, G.W. and Howell, S.A. (1999). Chronic urinary tract infection due to *Candida utilis*. *J. Clin. Microbiol.* 37, 824-827.
- Health Canada (2015). Natural Health Products Ingredients Database – Dried Torula Yeast. <http://webprod.hc-sc.gc.ca/nhp/nd-bdipsn/ingredReq.do?id=12547&lang=eng> (viewed February 2015)
- Hecht, T. and Viljoen, J. (1982). Observations on the suitability of various dry feeds for the commercial rearing of carp, *Cyprinus carpio* larvae in South Africa. *Water SA* 8, 58-65.
- Heilmann, C.J. Sorgo, A.G. Siliakus, A.R. Dekker, H.L. Brul, S. de Koster, C.G. de Koning, L.J. and Klis, F.M. (2011). Hyphal induction in the human fungal pathogen *Candida albicans* reveals a characteristic wall protein profile. *Microbiology* 157, 2297-2307.
- Helmerhorst, E.J. Venuleo, C. Sanglard, D. and Oppenheim, F.G. (2006). Roles of cellular respiration, CgCDR1, and CgCDR2 in *Candida glabrata* resistance to histatin 5. *Antimicrob. Agents Chemother.* 50, 1100-1103.
- Hepworth, L. (2012). A look into equine septic arthritis. Purdue University Indiana Animal Disease Diagnostic Laboratory. Fall 2012 Newsletter. <https://www.addl.purdue.edu/Newsletters/2012/Fall/Arthritis.aspx> (viewed April 2014).

- Holzschu, D.L. Chandler, F.W. Ajello, L. and Ahearn, D.G. (1979). Evaluation of industrial yeasts for pathogenicity. *Sabouraudia J. Med. Vet. Mycol.* 17, 71-78.
- Hoyer, L.L. (2001). The ALS gene family of *Candida albicans*. *Trends Microbiol.* 9, 176-180.
- Hube, B. and Naglik, J. (2001). *Candida albicans* proteinases: resolving the mystery of a gene family. *Microbiology* 147, 1997-2005.
- Ibrahim, A.S. Magee, B.B. Sheppard, D.C. Yang, M. Kauffman, S. Becker, J. Edwards, J.E.Jr, and Magee, P.T. (2005). Effects of ploidy and mating type on virulence of *Candida albicans*. *Infect. Immun.* 73, 7366-7374.
- Ibrahim, A.S. Mirbod, F. Filler, S.G. Banno, Y. Cole, G.T. Kitajima, Y. Edwards, J.E.Jr, Nozawa, Y. and Ghannoum, M.A. (1995). Evidence implicating phospholipase as a virulence factor of *Candida albicans*. *Infect. Immun.* 63, 1993-1998.
- Ignatova E.A. Nagornaia S.S. Sudenko V.I. Podgorskii V.S. (2002). [On the identity of *Candida utilis* and *Pichia jadinii* yeast species]. *Mikrobiol Z.* 6(1), 20-6.
- Ikushima, S. Fujii, T. and Kobayashi, O. (2009). Efficient gene disruption in the high-ploidy yeast *Candida utilis* using the Cre-loxP system. *Biosci. Biotechnol. Biochem.* 73, 879-884.
- Ikushima, S. Fujii, T. Kobayashi, O. and Ashigai, H. (2010). Method for highly efficient production of lactic acid using *Candida utilis*. CA Patent 2761724 A1.
- Jones, J. and Schmitt, J. (1978). The effect of chlorination on the survival of cells of *Candida albicans*. *Mycologia* 684-689.
- Kaliterna, J. Weusthuis, R.A. Castrillo, J.I. Van Dijken, J.P. and Pronk, J.T. (1995). Transient responses of *Candida utilis* to oxygen limitation: regulation of the Kluyver effect for maltose. *Yeast* 11, 317-325.
- Katila, M.L. Mantjarvi, R.A. and Ojanen, T.H. (1981). Sensitisation against environmental antigens and respiratory symptoms in swine workers. *Br. J. Ind. Med.* 38, 334-338.
- Keyhani, E. Khavari-Nejad, S. Keyhani, J. and Attar, F. (2009). Acriflavine-mediated apoptosis and necrosis in yeast *Candida utilis*. *Ann. New York Acad. Sci.* 1171, 284-291.
- Khan, T.R. and Daugulis, A.J. (2010). Application of solid-liquid TPPBs to the production of L-phenylacetylcarbinol from benzaldehyde using *Candida utilis*. *Biotechnol. Bioeng.* 107, 633-641.
- Kinneberg, K.M. Bendel, C.M. Jechorek, R.P. Cebelinski, E.A. Gale, C.A. Berman, J.G. Erlandsen, S.L. Hostetter, M.K. and Wells, C.L. (1999). Effect of *INT1* gene on *Candida albicans* murine intestinal colonization. *J. Surg. Res.* 87, 245-251.
- Koivikko, A. Kalimo, K. Nieminen, E. Savolainen, J. Viljanen, M. and Viander, M. (1988). Allergenic cross-reactivity of yeasts. *Allergy* 43, 192-200.
- Kondo, K. Saito, T. Kajiwarra, S. Takagi, M. and Misawa, N. (1995). A transformation system for the yeast *Candida utilis*: Use of a modified endogenous ribosomal protein gene as a drug-resistant marker and ribosomal DNA as an integration target for vector DNA. *J. Bacteriol.* 177, 7171-7177.
- Kong, Y. Xu, X. Zhu, L. and Miao, L. (2013). Control of the harmful alga *Microcystis aeruginosa* and absorption of nitrogen and phosphorus by *Candida utilis*. *Appl. Biochem. Biotechnol.* 169, 88-99.

- Kujan, P. Prell, A. Šafář, H. Sobotka, M. Řezanka, T. and Holler, P. (2006). Use of the industrial yeast *Candida utilis* for cadmium sorption. *Folia Microbiol.* **51**, 257-260.
- Kurtzman, C.P. (1988). Chapter 5: Identification and Taxonomy. In: Yeasts – (Living resources for biotechnology). Kirsop, B.E. and Kurtzman, C.P. Eds. Cambridge University Press. NY.
- Kurtzman, C.P. Johnson, C.J. and Smiley, M.J. (1979). Determination of conspecificity of *Candida utilis* and *Hansenula jadinii* through DNA reassociation. *Mycologia* **11**, 844-847.
- L'Ollivier, C. Labruère, C. Jebrane, A. Bounoux, M. d'Enfert, C. Bonnin, A. and Dalle, F. (2012). Using a Multi-Locus Microsatellite Typing method improved phylogenetic distribution of *Candida albicans* isolates but failed to demonstrate association of some genotype with the commensal or clinical origin of the isolates. *Infect. Genet. Evol.* **12**, 1949-1957.
- Laín, A. Elguezabal, N. Brena, S. García-Ruiz, J.C. del Palacio, A. Moragues, M.D. Pontón, J. (2007). Diagnosis of invasive candidiasis by enzyme-linked immunosorbent assay using the N-terminal fragment of *Candida albicans* hyphal wall protein I. *BMC Microbiol.* **7**, e35
- Lapena, M.A. Vicente-Soler, J. Soto, T. Madrid, M. Nunez, A. Garcia, E. Cansado, J. and Gacto, M. (2006). Light-induced rhythmic changes in thermotolerance in stationary-phase cells of *Candida utilis*. *Int. Microbiol.* **9**, 61-64.
- Lee, B.-. and Kyun Kim, J. (2001). Production of *Candida utilis* biomass on molasses in different culture types. *Aquacult. Eng.* **25**, 111-124.
- Leidich, S.D. Ibrahim, A.S. Fu, Y. Koul, A. Jessup, C. Vitullo, J. Fonzi, W. Mirbod, F. Nakashima, S. Nozawa, Y. and Ghannoum, M.A. (1998). Cloning and disruption of caPLB1, a phospholipase B gene involved in the pathogenicity of *Candida albicans*. *J. Biol. Chem.* **273**, 26078-26086.
- Lemmel, S.A. Heimsch, R.C. and Edwards, L.L. (1979). Optimizing the continuous production of *Candida utilis* and *Saccharomycopsis fibuliger* on potato processing wastewater. *Appl. Environ. Microbiol.* **37**, 227-232.
- Liu, Y. and Filler, S.G. (2011). *Candida albicans* Als3, a multifunctional adhesin and invasin. *Eukaryot. Cell.* **10**, 168-173.
- Lorenz, M.C. and Fink, G.R. (2001). The glyoxylate cycle is required for fungal virulence. *Nature* **412**, 83-86.
- Lukic-Grić, A. Mlinarić-Missoni, E. Škaric, I. Važić-Babić, V. and Svetec, I. (2011). *Candida utilis* Candidemia in neonatal patients. *J. Med. Microbiol.* **60**, 838-841.
- Luzzati, R. Cavinato, S. Giangreco, M. Granà, G. Centonze, S. Deiana, M.L. Biolo, G. and Barbone, F. (2013). Peripheral and total parenteral nutrition as the strongest risk factors for nosocomial Candidemia in elderly patients: a matched case-control study. *Mycoses* **56**, 664-671.
- Lyon, G.M. Karatela, S. Sunay, S. Adiri, Y. and *Candida* Surveillance Study Investigators. (2010). Antifungal susceptibility testing of *Candida* isolates from the *Candida* surveillance study. *J. Clin. Microbiol.* **48**, 1270-1275.
- Mahyuddin, P. and Winugroho, M. (2010). Effect of combination of yeast (*Saccharomyces cerevisiae* *Candida utilis*) and herbs supplementation in finishing diet on carcass characteristics of beef cattle. *J.Indones. Trop. Anim. Agric.* **35**, 251-256.

- Martin, A.M. Goddard, S. and Bemibster, P. (1993). Production of *Candida utilis* biomass as aquaculture feed. *J. Sci. Food Agric.* **61**, 363-370.
- Martinez, J. Nuñez, A. and Ojeda, D. Paper presented at Organic Fruit Conference 873.
- McDonnell, G. and Russell, A.D. (1999). Antiseptics and disinfectants: activity, action, and resistance. *Clin. Microbiol. Rev.* **12**, 147-179.
- Mille, Y. Beney, L. and Gervais, P. (2005). Compared tolerance to osmotic stress in various microorganisms: Towards a survival prediction test. *Biotechnol. Bioeng.* **92**, 479-484.
- Mohawed, S.M. (1994). Assessment of microbiological quality of underground water of upper Egypt, Qena region. *Egypt. J. Microbiol.* **29**, 183-192.
- Montagna, M.T. Lovero, G. Borghi, E. Amato, G. Andreoni, S. Campion, L. Lo Cascio, G. Lombardi, G. Luzzaro, F. Manso, E. (2014). Candidemia in intensive care unit: a nationwide prospective observational survey (GISIA-3 study) and review of the European literature from 2000 through 2013. *Eur. Rev. Med. Pharmacol. Sci.* **18**, 661-674.
- Mora, L.M. Lezcano, P. Hidalgo, K. and Rodríguez, B. (2012). *Torula* yeast (*Candida utilis*) on distiller's vinasse in growing pig diets. *Cuban J. Agric. Sci.* **46**, 63-65.
- Muter, O. Lubinya, I. Millers, D. Grigorjeva, L. Ventinya, E. and Rapoport, A. (2002). Cr(VI) sorption by intact and dehydrated *Candida utilis* cells in the presence of other metals. *Process Biochem.* **38**, 123-131.
- Nadeem, S.G. Shafiq, A. Hakim, S.T. Anjum, Y. and Kazm, S.U. (2013). Effect of growth media, pH and temperature on yeast to hyphal transition in *Candida albicans*. *Open J. Med. Microbiol.* **3**, 185-192.
- Naglik, J. Albrecht, A. Bader, O. and Hube, B. (2004). *Candida albicans* proteinases and host/pathogen interactions. *Cell. Microbiol.* **6**, 915-926.
- Naglik, J.R. Challacombe, S.J. and Hube, B. (2003). *Candida albicans* secreted aspartyl proteinases in virulence and pathogenesis. *Microbiol. Mol. Biol. Rev.* **67**, 400-28,
- NCYC. (2014). National Collection of Yeast Cultures. NYCY 707 *Lindnera jadinii* Product Sheet. <https://catalogue.ncyc.co.uk/lindnera-jadinii-707> (viewed January 2014).
- Nell, J.A. (1985). Comparison of some single cell proteins in the diet of the Sydney rock oyster (*Saccostrea commercialis*). *The Progressive Fish-Culturist* **47**, 110-113.
- Nell, J.A. Diemar, J.A. and Heasman, M.P. (1996). Food value of live yeasts and dry yeast-based diets fed to Sydney rock oyster *Saccostrea commercialis* spat. *Aquaculture* **145**, 235-243.
- Nie, W. Wei, G. Du, G. Li, Y. and Chen, J. (2005). Enhanced intracellular glutathione synthesis and excretion capability of *Candida utilis* by using a low pH-stress strategy. *Lett. Appl. Microbiol.* **40**, 378-384.
- Nie, X. Liu, X. Wang, H. and Chen, J. (2010). Deletion of EFG1 promotes *Candida albicans* opaque formation responding to pH via Rim101. *Acta Biochim. Biophys. Sin. (Shanghai)* **42**, 735-744.
- Nobile, C.J. Schneider, H.A. Nett, J.E. Sheppard, D.C. Filler, S.G. Andes, D.R. and Mitchell, A.P. (2008). Complementary adhesin function in *C. albicans* biofilm formation. *Curr. Biol.* **18**, 1017-1024.

- Nwachukwu, S. (2000). Enhanced rehabilitation of tropical aquatic environments polluted with crude petroleum using *Candida utilis*. J. Environ. Biol. 21, 241-250.
- Oberoi, J.K. Wattal, C. Goel, N. Raveendran, R. Datta, S. and Prasad, K. (2012). Non-albicans *Candida* species in blood stream infections in a tertiary care hospital at New Delhi, India. Indian J. Med. Res. 136, 997-1003.
- Odds, F.C. Hanson, M.F. Davidson, A.D. Jacobsen, M.D. Wright, P. Whyte, J.A. Gow, N.A. and Jones, B.L. (2007). One year prospective survey of *Candida* bloodstream infections in Scotland. J. Med. Microbiol. 56, 1066-1075.
- Odds, F.C. and Jacobsen, M.D. (2008). Multilocus sequence typing of pathogenic *Candida* species. Eukaryot. Cell. 7, 1075-1084.
- Oliva, R.U. and Hang, Y.D. (1979). Continuous removal of lactic acid from wastewater by *Candida utilis*. Appl. Environ. Microbiol. 38, 1027-1028.
- Olvera-Novoa, M.A. Martínez-Palacios, C.A. and Olivera-Castillo, L. (2002). Utilization of torula yeast (*Candida utilis*) as a protein source in diets for tilapia (*Oreochromis mossambicus* Peters) fry. Aquacult. Nutr. 8, 257-264.
- Ordaz, L. Lopez, R. Melchy, O. and Torre, M. (2001). Effect of high-cell-density fermentation of *Candida utilis* on kinetic parameters and the shift to respiro-fermentative metabolism. Appl. Microbiol. Biotechnol. 57, 374-378.
- Øverland, M. Karlsson, A. Mydland, L.T. Romarheim, O.H. and Skrede, A. (2013). Evaluation of *Candida utilis*, *Kluyveromyces marxianus* and *Saccharomyces cerevisiae* yeasts as protein sources in diets for Atlantic salmon (*Salmo salar*). Aquaculture 402-403, 1-7.
- Pan, L. Yang, D. Shao, L. Li, W. Chen, G. and Liang, Z. (2009). Isolation of the oleaginous yeasts from the soil and studies of their lipid-producing capacities. Food Technol Biotechnol 47, 215-220.
- Paulitsch, A. Weger, W. Ginter-Hanselmayer, G. Marth, E. and Buzina, W. (2006). A 5-year (2000-2004) epidemiological survey of *Candida* and non-*Candida* yeast species causing vulvovaginal candidiasis in Graz, Austria. Mycoses 49, 471.
- Paulitsch, A.H. Willinger, B. Zsasz, B. Stabentheiner, E. Marth, E. and Buzina, W. (2009). In-vivo *Candida* biofilms in scanning electron microscopy. Med. Mycol. 47, 690-696.
- Peng, Y.S. Nasr, M.E. Marston, J.M. and Fang, Y. (1984). Digestion of torula yeast, *Candida utilis*, by the adult honeybee, *Apis mellifera*. Ann. Entomol. Soc. Am. 77, 627-632.
- Pfaller, M. Neofytos, D. Diekema, D. Azie, N. Meier-Kriesche, H. Quan, S. and Horn, D. (2012). Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004–2008. Diagn. Microbiol. Infect. Dis. 74, 323-331.
- Pfaller, M.A. Moet, G.J. Messer, S.A. Jones, R.N. and Castanheira, M. (2011). Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among *Candida* bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). J. Clin. Microbiol. 49, 396-399.
- Pharkya, P. Burgard, A.P. Van Dien, S.J. Osterhout, R.E. Burk, M.J. Trawick, J.T. and Kuchinskas, B.S. (2014). Microorganisms and methods for production of 4-hydroxybutyrate, 1,4-butanediol and related compounds. US Patent 20140030779 A1.

Pisman, T. and Somova, L. (2003). Interaction of a mixed yeast culture in an “autotroph-heterotroph” system with a closed atmosphere cycle and spatially separated components. *Adv.Space Res.* 31, 1751-1756.

Prasad, R. De Wergifosse, P. Goffeau, A. and Balzi, E. (1995). Molecular cloning and characterization of a novel gene of *Candida albicans*, CDR1, conferring multiple resistance to drugs and antifungals. *Curr. Genet.* 27, 320-329.

Presterl, E. Daxböck, F. Graninger, W. and Willinger, B. (2007). Changing pattern of candidaemia 2001–2006 and use of antifungal therapy at the University Hospital of Vienna, Austria. *Clin. Microbiol. Infec.* 13, 1072-1076.

Product Sheet. (2014a). Agrisent Product Sheet for Inactive Torula Yeast. http://www.agrisent.com/index_files/Page624.htm (viewed May 2014).

Product Sheet. (2014b). Aliments ED Foods Product Sheet for Luda Original Cream Soup and Sauce Base. <http://www.ed.ca/our-products/our-brands/luda-original/cream-soup-sauce-base-b5bd3edd.html> (viewed May 2014).

Product Sheet. (2014c). Lallemand Product Data Sheet for Lake States Torula Yeast. http://www.bio-lallemand.com/wp-content/uploads/2012/05/PDSLakeState12_low.pdf (viewed May 2014).

Product Sheet. (2014d). Ohly Product Sheet for Autolyzed Torula Yeast. <http://www.ohly.com/products-services/autolysed-yeast> (viewed May 2014).

Product Sheet. (2014e). Hillestad Pharmaceuticals Product Sheet for Arise Vigor/Force Protein Energy Mixer. <http://www.hillestadlabs.com/protein%20products.html> (viewed May 2014).

Product Sheet. (2014f). Nature's Choice Product Sheet for Torula Yeast Probiotic. <http://www.natureschoice.co.za/bio-friendly/seasonings/torula-yeast/> (viewed May 2014).

Product Sheet. (2014g). North American Herb and Spice Product Sheet for Purely B. <http://www.northamericanherbandspice.com/product/purely-b-400-g-powder/> (viewed May 2014).

Product Sheet. (2014h). Phytovie Product Sheet for Gourmet Nutrition Torula Yeast. <http://www.phytovie.ca/product/5239> (viewed May 2014).

Product Sheet. (2014i). Kohjin Life Sciences Co. Ltd. Product Sheet for HITHION YH-15. http://www.kohjinls.com/en/business/hithionextract_yh.html (viewed May 2014).

Rahman, S.A. (1996). Evaluation of various diets for the optimum growth and survival of larvae of the penaeid prawn *Penaeus japonicus* Bate. *Aquacult. Nutr.* 2, 151-155.

Ramage, G. Bachmann, S. Patterson, T.F. Wickes, B.L. and Lopez-Ribot, J.L. (2002). Investigation of multidrug efflux pumps in relation to fluconazole resistance in *Candida albicans* biofilms. *J. Antimicrob. Chemother.* 49, 973-980.

Ramírez-Zavala, B. Reuß, O. Park, Y. Ohlsen, K. and Morschhäuser, J. (2008). Environmental induction of white–opaque switching in *Candida albicans*. *PLoS Pathogens* 4(6), e1000089.

Razif, M. Budiarti, V.E. and Mangkoedihardjo, S. (2006). Appropriate fermentation process for tapioca's wastewater in Indonesia. *J. Appl. Sci.* 6, 2846-2848.

Restaino, L. Frampton, E.W. Hemphill, J.B. and Palnikar, P. (1995). Efficacy of ozonated water against various food-related microorganisms. *Appl. Environ. Microbiol.* 61, 3471-3475.

Ribeiro, I.C. Veríssimo, I. Moniz, L. Cardoso, H. Sousa, M.J. Soares, A.M.V.M. and Leão, C. (2000). Yeasts as a model for assessing the toxicity of the fungicides penconazol, cymoxanil and dichlofluanid. *Chemosphere* **41**, 1637-1642.

Riggle, P.J. and Kumamoto, C.A. (2006). Transcriptional regulation of MDR1, encoding a drug efflux determinant, in fluconazole-resistant *Candida albicans* strains through an Mcm1p binding site. *Eukaryot. Cell* **5**, 1957-1968.

Rodríguez, B. Valdivié, M. Lezcano, P. and Herrera, M. (2013). Evaluation of torula yeast (*Candida utilis*) grown on distillery vinasse for broilers. *Cuban J. Agric. Sci.* **47**,

Ruszova, E. Pavék, S. Hajkova, V. Jandova, S. Velebny, V. Papezikova, I. and Kubala, L. (2008). Photoprotective effects of glucomannan isolated from *Candida utilis*. *Carbohydr. Res.* **343**, 501-511.

Sanglard, D. Ischer, F. Monod, M. and Bille, J. (1997). Cloning of *Candida albicans* genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. *Microbiology* **143** (Pt 2), 405-416.

Savolainen, J. Kortekangas-Savolainen, O. Nermes, M. Viander, M. Koivikko, A. Kalimo, K. and Terho, E.O. (1998). IgE, IgA, and IgG responses to common yeasts in atopic patients. *Allergy Eur. J. Allergy Clin. Immunol.* **53**, 506-512.

Schaller, M. Hube, B. Ollert, M.W. Schäfer, W. Borg-von Zepelin, M. Thoma-Greber, E. and Korting, H.C. (1999). In vivo expression and localization of *Candida albicans* secreted aspartyl proteinases during oral candidiasis in HIV-infected patients. *J. Invest. Dermatol.* **112**, 383-386.

Şeker, E. (2010). Identification of *Candida* species isolated from bovine mastitic milk and their in vitro hemolytic activity in Western Turkey. *Mycopathologia* **169**, 303-308.

Sharma, N. Verma, U. and Awasthi, P. (2006). A combination of the yeast *Candida utilis* and chitosan controls fruit rot in tomato caused by *Alternaria alternata* (Fr.) Keissler and *Geotrichum candidum* Link ex Pers. *J.Hortic.Sci.Biotechnol.* **81**, 1052-1056.

Sheppard, D.C. Locas, M.C. Restieri, C. and Laverdiere, M. (2008). Utility of the germ tube test for direct identification of *Candida albicans* from positive blood culture bottles. *J. Clin. Microbiol.* **46**, 3508-3509.

Shih, M.H. Sheu, M.M. Chen, H.Y. and Lin, S.R. (1999). Fungal keratitis caused by *Candida utilis*--case report. *Kaohsiung J. Med. Sci.* **15**, 171-174.

Singh, A. Prasad, T. Kapoor, K. Mandal, A. Roth, M. Welti, R. and Prasad, R. (2010). Phospholipidome of *Candida* : Each species of *Candida* has distinctive phospholipid molecular species. *OMICS J. Integr. Biol.* **14**, 665-677.

SivaRaman, H. Pundle, A.V. and Prabhune, A.A. (1984). Growth of *Candida utilis* on distillery effluent. *Biotechnol. Lett.* **6**, 759-762.

Siwicki, A.K. Anderson, D.P. and Rumsey, G.L. (1994). Dietary intake of immunostimulants by rainbow trout affects non-specific immunity and protection against furunculosis. *Vet. Immunol. Immunopathol.* **41**, 125-139.

Song, X. Sun, J. Støre, G. Hansen, B.F. and Olsen, I. (2009). Colony morphologies, species, and biotypes of yeasts from thrush and denture stomatitis. *Acta Odontol. Scand.* **67**, 248-255.

Spampinato, C. and Leonardi, D. (2013). Molecular fingerprints to identify *Candida* species. *BioMed Res. Int.* 2013, 1-9.

Staab, J.F. Ferrer, C.A. and Sundstrom, P. (1996). Developmental expression of a tandemly repeated, proline-and glutamine-rich amino acid motif on hyphal surfaces on *Candida albicans*. *J. Biol. Chem.* 271, 6298-6305.

Stevens, R.I. and Truog, J.R. (1957). Comparison of dried yeasts, *Candida utilis* and *Saccharomyces cerevisiae*, as supplements in a diet for Rainbow Trout. *Trans. Am. Fish. Soc.* 86, 161-168.

Stevenson, K. Black, O. and Costilow, R. (1979). Aerobic fermentations of pickle process brine by *Candida utilis*. *J. Food Sci.* 44, 181-185.

Streit, J. Prior, B.A. and Kilian, S.G. (1987). Substrate utilization by yeast in a spent sulfite liquor permeate. *Water SA (Pretoria)* 13, 145-150.

Sudbery, P. (2011). Growth of *Candida albicans* hyphae. *Nature Rev. Microbiol.* 9, 737-748.

Sudbery, P. Gow, N. and Berman, J. (2004). The distinct morphogenic states of *Candida albicans*. *Trends Microbiol.* 12(7), 317-324.

Sukorinia, H. Sangchote, S. and Khewkhomc, N. (2013). Control of postharvest green mold of citrus fruit with yeasts, medicinal plants, and their combination. *Postharvest Biol. Technol.* 79, 24-31.

Suzuki, M. and Nakase, T. (2002). A phylogenetic study of ubiquinone-7 species of the genus *Candida* based on 18S ribosomal DNA sequence divergence. *J. Gen. Appl. Microbiol.* 48, 55-65.

Szyłak-Szydłowski, M. and Kornilłowicz-Kowalska, T. (2012). The mycobiota of landfill leachates in the pretreatment process in a sequencing batch reactor. *Cent. Eur. J. Biol.* 7, 250-258.

Tavanti, A. Davidson, A.D. Gow, N.A. Maiden, M.C. and Odds, F.C. (2005). *Candida orthopsilosis* and *Candida metapsilosis* spp. nov. to replace *Candida parapsilosis* groups II and III. *J. Clin. Microbiol.* 43, 284-292.

Tavanti, A. Gow, N.A. Senesi, S. Maiden, M.C. and Odds, F.C. (2003). Optimization and validation of multilocus sequence typing for *Candida albicans*. *J. Clin. Microbiol.* 41, 3765-3776.

Thewes, S. Moran, G.P. Magee, B.B. Schaller, M. Sullivan, D.J. and Hube, B. (2008). Phenotypic screening, transcriptional profiling, and comparative genomic analysis of an invasive and non-invasive strain of *Candida albicans*. *BMC Microbiol.* 8, 187-2180-8-187.

Tomita, Y. Ikeo, K. Tamakawa, H. Gojobori, T. and Ikushima, S. (2012). Genome and transcriptome analysis of the food-yeast *Candida utilis*. *PLoS One* 7, e37226.

Tortorano, A.M. Caspani, L. Rigoni, A.L. Biraghi, E. Sicignano, A. and Viviani, M.A. (2004). Candidosis in the intensive care unit: A 20-year survey. *J. Hosp. Infect.* 57, 8-13.

Turkylmaz, S. and Kaynarca, S. (2010). The slime production by yeasts isolated from subclinical mastitic cows. *Acta Veterinaria Brno* 79, 581-586.

Uetsuka, A. Satoh, S. Itoh, M. Okazaki, N. Ohno, Y. and Yoshimura, K. (1976). The tissue culture study of antifungal agents and their morphological changes on yeast and yeast-like fungi. In: *Parasites, Fungi, and Viruses*, Springer) pp. 157-163.

Urban Jr, E.R. and Langdon, C.J. (1984). Reduction in costs of diets for the American oyster, *Crassostrea virginica* (Gmelin), by the use of non-algal supplements. *Aquaculture* 38, 277-291.

U.S.D.A. ARS. (2014). United States Department of Agriculture. Agriculture Research Services Culture Collection (NRRL). <http://nrml.ncaur.usda.gov/cgi-bin/usda/yeast/report.html?nrmlcodes=Y-900> (viewed March 2014).

U.S. FDA. (2013). United States Food and Drug Administration. Code of Federal Regulations Title 21 Part 127: Food Additives Permitted for Direct Addition to Food for Human Consumption (21CFR172.896). (<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?fr=172.896> (viewed April 2014)).

Verweij, P.E. van den Bergh, M.F. Rath, P.M. de Pauw, B.E. Voss, A. and Meis, J.F. (1999). Invasive aspergillosis caused by *Aspergillus ustus*: case report and review. *J. Clin. Microbiol.* 37, 1606-1609.

Visser, W. Scheffers, W.A. Batenburg-van der Vegte, W.H. and van Dijken, J.P. (1990). Oxygen requirements of yeasts. *Appl. Environ. Microbiol.* 56, 3785-3792.

Vraná, D. and Sobotka, M. (1989). Physiological changes of *Candida utilis* in transient state during continuous cultivation. *Folia Microbiol* 34, 30-36.

Vylkova, S. Carman, A.J. Danhof, H.A. Collette, J.R. Zhou, H. and Lorenz, M.C. (2011). The fungal pathogen *Candida albicans* autoinduces hyphal morphogenesis by raising extracellular pH. *mBio.* 2(3), 1-12.

Watts, J.L. (1988). Etiological agents of bovine mastitis. *Vet. Microbiol.* 16, 41-66.

Wawron, W. Bochniarz, M. and Piech, T. (2010). Yeast mastitis in dairy cows in the middle-eastern part of Poland. *Bulletin of the Veterinary Institute in Puławy* 54, 201-204.

Westwater, C. Balish, E. and Schofield, D.A. (2005). *Candida albicans*-conditioned medium protects yeast cells from oxidative stress: a possible link between quorum sensing and oxidative stress resistance. *Eukaryot. Cell.* 4, 1654-1661.

Weusthuis, R.A. Visser, W. Pronk, J.T. Scheffers, W.A. and van Dijken, J.P. (1994). Effects of oxygen limitation on sugar metabolism in yeasts: a continuous-culture study of the Kluyver effect. *Microbiology* 140 (Pt 4), 703-715.

Whiteway, M. and Bachewich, C. (2007). Morphogenesis in *Candida albicans*. *Annu. Rev. Microbiol.* 61, 529-553.

Wirsching, S. Michel, S. and Morschhäuser, J. (2000). Targeted gene disruption in *Candida albicans* wild-type strains: the role of the MDR1 gene in fluconazole resistance of clinical *Candida albicans* isolates. *Mol. Microbiol.* 36, 856-865.

Yamada, Y. Matsuda, M. and Mikata, K. (1995). The phylogenetic relationships of *Pichia jadinii*, formerly classified in the genus *Hansenula*, and related species based on the partial sequences of 18S and 26S ribosomal RNAs (*Saccharomycetaceae*). *Biosci. Biotechnol. Biochem.* 59, 518-520.

Yurong, Y. Ruiping, S. Shimin, Z. and Yibao, J. (2005). Effect of probiotics on intestinal mucosal immunity and ultrastructure of cecal tonsils of chickens. *Arch. Anim. Nutr.* 59, 237-246.


Zheng, S. Yang, M. Lv, W. and Liu, F. (2001). Study on sludge expansion during treatment of salad oil manufacturing wastewater by yeast. *Environ. Technol.* 22, 533-542.

Zhou, Y. Ren, Y. Fan, C. Shao, H. Zhang, Z. Mao, W. Wei, C. Ni, H. Zhu, Z. Hou, X. Piao, F. and Cui, Y. (2013). Survey of mycotic mastitis in dairy cows from Heilongjiang Province, China. *Trop. Anim. Health Pro.* *45*, 1709-1714.

Appendices

Appendix A: Characterization *C. utilis* ATCC 9950

a) *C. utilis* ATCC 9950^a



b) *C. albicans* SC5314^a



Figure 0-1: Photomicrographs showing differential growth of a) *C. utilis* ATCC 9950 and b) *C. albicans* SC5314 on Corn Meal-Tween 80 Agar at 37°C for 72 h

^a Data generated by Health Canada's Healthy Environments and Consumer Safety Branch.

Table 0-1: Growth of *C. utilis* ATCC 9950 on various media and temperatures

Medium	28°C	32°C	37°C	42°C
Sabouraud	+	+	+	-
Fetal Bovine Serum	+	+	~	-
Dulbecco's Modified Eagles Medium (with FBS, glucose, glutamine)	~	~	-	-

+ Growth - No growth ~ Low level of growth

Data generated by Health Canada's Healthy Environments and Consumer Safety Branch. Growth of *C. utilis* ATCC 9950 in various media was measured by increase in absorbance at 500 nm over a range of temperatures. Concentration of bacteria at time zero was 1×10^6 CFU/mL.